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Abstract 
The tumour suppressor p53 is a major transcription factor activated in response to cellular 
stresses to induce cell cycle arrest, senescence, and apoptosis. TP53 is the most frequently 
mutated gene in human cancers. Actually, about half of all human tumours express inactive 
mutant forms of the p53 tumour suppressor, which often correlates with high resistance to 
conventional chemotherapy and poor prognosis. Additionally, in tumours retaining a wild-
type p53 status, the activity of this protein is suppressed due to the overexpression of two 
structurally related p53-negative regulators, murine double minute (MDM)2 and MDMX. 
The simultaneous inhibition of the interactions of MDM2 and MDMX with p53, resulting in a 
full p53 reactivation represents a promising anticancer strategy, due to the critical and non-
redundant role of these negative modulators. In this work, from the screening of a small 
library of tryptophanol-derived oxazolopiperidone lactams, using a yeast target-directed 
approach, a potential dual inhibitor of the p53 interaction with MDM2 and MDMX, the N-
tosylindole OXAZ-1, was discovered. OXAZ-1 exhibited a p53-dependent in vitro antitumour 
activity against tumours retaining wild-type p53 and distinct levels of MDM2 and MDMX. 
The promising antitumour activity of OXAZ-1 was reinforced by its ability to trigger a 
mitochondria-mediated apoptotic cell death and to sensitize tumour cells to the effects of 
conventional chemotherapeutic drugs. The N-tosylindole OXAZ-1 opens the way to the 
development of a new class of dual MDM2/MDMX inhibitors, with promising applications in 
anticancer therapy. 
An additional outcome of this work was the development of new yeast target-directed 
screening assays for reactivators of some of the most prevalent human mutant p53 forms, 
namely R280K, R175H, R273H and Y220C. The pharmacological restoration of the wild-
type activity to mutant p53 is an appealing and selective anticancer therapeutic strategy, 
since besides their high prevalence, expression of p53 mutants is restricted to tumour cells. 
The developed yeast target-directed screening assays may also represent a relevant tool 
for the further elucidation of the mutant p53 network, since the biology of p53 mutants 
remains largely unknown. 
 
Keywords: anticancer agents; p53-MDM2 interaction; p53-MDMX interaction; mutant p53; 
tumour suppressor proteins; yeast target-directed assays  
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Resumo 
A proteína supressora tumoral p53 representa um dos principais fatores de transcrição 
ativados em resposta a stresses celulares levando à paragem do ciclo celular, senescência 
e apoptose. O gene TP53 é o mais comumente mutado em cancros humanos. De facto, 
cerca de metade dos cancros humanos expressa uma forma mutada da proteina 
oncossupressora p53, a qual está frequentemente associada a resistências à quimioterapia 
e a um mau prognóstico. Para além disso, em tumores que mantêm a forma nativa da p53, 
a atividade da proteína é suprimida devido à sobrexpressão de dois reguladores negativos 
estruturalmente relacionados, murine double minute (MDM)2 e MDMX. 
A inibição simultânea da interação das proteínas MDM2 e MDMX com a p53 nativa 
representa uma estratégia promissora no tratamento do cancro, tendo em conta as funções 
distintas e cruciais destes moduladores negativos da p53. Neste trabalho, a partir da 
análise de uma biblioteca de compostos derivados da família química triptofanol 
oxazolopiperidona lactamas, e usando o modelo de pesquisa direcionada com células de 
levedura, foi descoberto um potencial inhibidor dual da interação da p53 com MDM2 e 
MDMX, o composto N-tosilindole OXAZ-1. O OXAZ-1 exibe atividade antitumoral in vitro 
dependente da p53 em células tumorais que possuem a p53 nativa e diferentes níveis de 
MDM2 e MDMX. A promissora atividade antitumoral do composto OXAZ-1 foi reforçada 
pela sua capacidade de ativar a via apoptótica mitocondrial e de sensibilizar as células 
tumorais para os efeitos de quimioterápicos convencionais. O composto N-tosilindole 
OXAZ-1 abre assim caminho para o desenvolvimento de uma nova classe de inibidores 
duais de MDM2/MDMX, com promissora aplicabilidade em terapias antitumorais. 
Para além disso, neste trabalho, foi desenvolvido um novo modelo de levedura para a 
pesquisa de reativadores de algumas das formas mutadas mais prevalentes da p53 
humana, nomeadamente R280K, R175H, R273H e Y220C. A restituição farmacólogica da 
função nativa da p53 é uma estratégia apelativa e seletiva no tratamento de tumores que 
expressam mutantes da p53, uma vez que, para além de serem muito prevalentes, a 
expressão de formas mutadas da p53 é restrita a células tumorais. O modelo de levedura 
aqui desenvolvido pode também representar uma valiosa estratégia para estudos 
funcionais das mutantes da p53, uma vez que muitos aspetos biológicos de formas 
mutadas da p53 continuam amplamente desconhecidos. 
 
Palavras-chave: agentes anticancerígenos; interação p53-MDM2; interação p53-MDMX; 
p53 mutante; proteínas supressoras tumorais; modelo de levedura para pesquisa 
direcionada 
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1 General introduction 
1.1  Cancer epidemiology and general concepts about cancer 
Cancer is the leading cause of death in economically developed countries and the second 
in developing countries. Despite the improvement in the relative survival rates for many 
cancer types, cancer prevalence is increasing in economically developed countries as a 
result of population aging and growth, as well as an increased adoption of cancer-
associated lifestyle choices including smoking, physical inactivity, and ‘‘westernized’’ diets. 
According to the World Health Organization, in 2012, there were 14.1 million new cancer 
cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years 
of diagnosis). In the same year, in Europe, 3.7 million new cases of cancer were diagnosed 
and 1.9 million people died with the disease. In Portugal, there were 49.2 thousand new 
cancer cases, 24.1 thousand cancer deaths and 134.3 thousand people living with the 
disease (Bray et al., 2012; Ferlay et al., 2013; Soussi and Béroud, 2012). These statistics 
data may justify why cancer has been the focus of an intense worldwide scientific research. 
During development and cellular proliferation there is an intrinsic control system that 
regulates the balance between cell division and death in response to growth signals. The 
loss of this balance is the basis of carcinogenesis, a multistage process, involving oncogene 
activation and tumour suppressor gene inactivation that promotes cell proliferation and/or 
impairs apoptosis. This process also involves complex interactions between tumour and 
host tissues, ultimately leading to an aggressive metastatic phenotype [reviewed in (Wang 
and Sun, 2010)]. 
A normal cell needs to acquire several characteristics, called hallmarks of cancer, in order 
to progress to a cancer cell (Figure 1). In 2000, six hallmark capabilities were originally 
proposed, namely self-sufficiency in growth signals, insensitivity to anti-growth signals, 
evasion of apoptosis, limitless replicative potential, sustained angiogenesis and tissue 
invasion and metastasis (Figure 1). However, recent data support that there are two 
additional hallmarks of cancer, named emerging hallmarks, involved in the pathogenesis of 
perhaps all cancers. One involves the capability to modify, or reprogram, cellular 
metabolism in order to most effectively support neoplasic proliferation, and the second 
allows cancer cells to evade immunological destruction. Additionally, two consequential 
characteristics of neoplasia facilitate acquisition of both core and emerging hallmarks. 
Genomic instability and thus mutability endow cancer cells with genetic alterations that drive 
tumour progression. Inflammation by innate immune cells designed to fight infections and 
heal wounds can instead result in their inadvertent support of multiple hallmark capabilities, 
thereby manifesting the now widely appreciated tumour-promoting consequences of 
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inflammatory responses (Figure 1). Each of these new abilities acquired during cancer 
development represents the successful breaching of an anticancer defence mechanism 
hardwired into cells and tissues [reviewed in (Hanahan and Weinberg, 2000; Hanahan and 
Weinberg, 2011)]. 
 
 
 
1.2  The p53 tumour suppressor protein: A major therapeutic target in cancer 
Despite the huge diversity of tumour suppressor genes implicated in carcinogenesis, the 
TP53 gene, which encodes the transcription factor p53, has been shown to play a pivotal 
role protecting cells against cancer development [reviewed in (Suzuki and Matsubara, 
2011)]. 
Figure 1. The hallmarks of cancer. This illustration encompasses the ten hallmark capabilities currently 
proposed. Some of these critical features are: self-sufficiency in growth signals, insensitivity to anti-growth 
signals, evasion of apoptosis, limitless replicative potential, genome instability and mutation, sustained 
angiogenesis, tissue invasion and metastasis [adapted from (Hanahan and Weinberg, 2011)] 
 
Figure 2. Schematic representation of p53 functions in tumour prevention, suppression and 
development. When activated by stress signals, p53 can halt the cell cycle and initiate the DNA repair. 
Under a successful repair, the cell cycle is restarted, and the cellular and genomic stability are re-
established. When the damage is too extensive and the repair is not an option, cells induce the killer 
function of p53 to activate apoptosis or senescence. This activation results in the permanent elimination 
of damage cells. Both apoptosis and senescence have been linked to tumour suppression, whereas the
cell cycle arrest has been linked to tumour prevention. Notably, the protective functions of p53 may 
contribute to tumour development if not properly regulated (dashed arrow).Figure 3. The hallmarks of 
cancer  This illustration encompasses the ten hallmark capabilities currently proposed. Some of these 
critical features are: self-sufficiency in growth signals, insensitivity to anti-growth signals, evasion of 
apoptosis, limitless replicative potential, genome instability and mutation, sustained angiogenesis, tissue 
invasion and metastasis [adapted from (Hanahan and Weinberg, 2011)] 
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The TP53 gene was the first tumour suppressor gene identified. First described in 1979, it 
was initially reported as a protein interacting with the oncogenic T antigen from SV40 virus 
(Lane and Crawford, 1979; Linzer and Levine, 1979). Based on these observations, p53 
began to be classified as an oncogene, with many studies describing proliferative and 
transforming activities of the protein. However, this classical point of view has been 
challenged by the findings that the initially discovered p53 was a mutant (mut) and not the 
wild-type (wt) form, as was originally considered. Only ten years later, subsequent studies 
revealed that the wt p53 is capable to suppress the malignant growth of transformed cells 
as well as tumours, supporting the fact that p53 is a potent tumour suppressor instead of 
an oncogene [reviewed in (Bourdon, 2007; Freed-Pastor and Prives, 2012)]. 
The human TP53 gene, located at position 17p13.1 of the small arm of chromosome 17, 
has been called the “guardian of the genome”, due to its pivotal role in maintaining genomic 
stability and tumour prevention [reviewed in (Bourdon, 2007; Freed-Pastor and Prives, 
2012)]. Indeed, the p53 tumour suppressor acts as a major regulator in a complex signalling 
pathway that involves to sense a broad range of cellular stresses such as DNA damage, 
hypoxia, nutritional deprivation, nucleotide depletion or oncogene activation (Figure 2) 
[reviewed in (Amaral et al., 2010; Liu et al., 2014; Suzuki and Matsubara, 2011)].  
In the absence of cellular stresses, the p53 protein is kept at low steady-levels, through the 
interaction with murine double minute (MDM) proteins, and exerts little effect on cell fate. 
However, upon exposure to these countless cellular stress signals, and depending on the 
tissue-type and the extension of the damage, p53 undergoes post-translational 
modifications that leads to its stabilization and activation, namely phosphorylation, 
acetylation and methylation, among others. Once activated, p53 is able to inhibit cell cycle 
progression, promote senescence, or induce apoptotic cell death, in order to prevent the 
replication of damaged DNA or the proliferation of genetically altered cells that could lead 
to tumour formation and development (Figure 2) [reviewed in (Bourdon, 2007; Brosh and 
Rotter, 2009; Freed-Pastor and Prives, 2012)]. Actually, when the DNA damage is too 
profound to be successfully repaired by cell cycle arrest, p53 triggers apoptosis. However, 
when p53 is mutated or absent, damaged cells become resistant to apoptosis and survive 
(Figure 2) [reviewed in (Amaral et al., 2010)].  
The TP53 gene is inactivated by mutation or deletion in nearly 50% of human cancers. In 
the remaining cases, p53 retains its wt status but its function is compromised by distinct 
mechanisms, as the overexpression of its two major negative regulators, the homologs 
MDM2 and MDMX [reviewed in (Shadfan et al., 2012)]. 
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Furthermore, the TP53 gene belongs to a highly conserved gene family containing at least 
two related genes, TP63 and TP73 (encoding p63 and p73, respectively) [reviewed in 
(Bourdon, 2007; Freed-Pastor and Prives, 2012; Millau et al., 2009)]. Actually, the 
exogenous expression of p63 or p73 causes growth arrest, apoptosis, and differentiation, 
which are often due to the transcriptional activation of p53 target genes (Strano et al., 2002). 
To date, both p63 and p73 have been found rarely mutated in human tumours (Gaiddon et 
al., 2001; Strano et al., 2002). However, several forms of mut p53 were reported to interact 
with p63 and p73 through their DNA-binding domain, inhibiting their transcriptional activities 
(Gaiddon et al., 2001; Strano et al., 2002). 
Figure 2. Schematic representation of p53 functions in tumour prevention, suppression and 
development. When activated by stress signals, p53 can halt the cell cycle and initiate the DNA repair. 
Under a successful repair, the cell cycle is restarted, and the cellular and genomic stability are re-
established. When the damage is too extensive and the repair is not an option, cells induce the killer 
function of p53 to activate apoptosis or senescence. This activation results in the permanent elimination 
of damage cells. Both apoptosis and senescence have been linked to tumour suppression, whereas the 
cell cycle arrest has been linked to tumour prevention. Notably, the protective functions of p53 may 
contribute to tumour development if not properly regulated (dashed arrow). 
 
Figure 4. Schematic representation of the domain structure of p53. The human p53 protein 
comprises several well-defined domains, including an N-terminal transactivation domain (TAD), followed 
by a central core DNA-binding domain, an oligomerization domain and a basic domain at the extreme C-
terminus. The p53 TAD is able to mediate p53 transcriptional activity and to regulate its stability through 
interaction with components of the transcription initiation complex, with co-activators, such as p300 and 
CBP, and with several regulatory proteins, such as MDM2 and MDMX.Figure 5. Schematic 
representation of p53 functio s in tumour prevention, suppression and devel pment. When 
activated by stress signals, p53 can halt the cell cycle and initiate the DNA repair. Under a successful 
repair, the cell cycle is restarted, and the cellular and genomic stability are re-established. When the 
damage is too extensive and the repair is not an option, cells induce the killer function f p53 t  activate 
apoptosis or senescence. This activation results in the permanent elimination of damage cells. Both 
apoptosis and senescence have been linked to tumour suppression, whereas the cell cycle arrest has 
been linked to tumour preventi n. Notably, the protective functions of p53 may contribute to tumour 
development if not properly regulated (dashed arrow). 
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Therefore, the dynamic and multiple functions of p53, highlight the importance in 
understanding its activity, since the loss of p53 function can lead to more aggressive cancer 
forms or to chemotherapy resistance making of p53 one of the most appealing therapeutic 
targets in cancer therapy [reviewed in (Amaral et al., 2010)].  
 
1.3  Structural organization of p53 protein 
The 393-amino acid p53 protein has a complex domain structure, which can be 
schematically divided into three main domains (Figure 3): the N-terminal transactivation 
domain (TAD), the core DNA-binding domain (DBD), the most conserved region of the p53 
protein, and the C-terminal domain [reviewed in (Millau et al., 2009)]. Each of these domains 
plays an important role in p53 function. 
 
 
 
The N-terminal domain consists of two continuous transactivation subdomains (TADI and 
TADII) followed by an adjacent proline-rich domain (Figure 3). In fact, it has been shown 
that the transactivation function of wt p53 is dependent on four critical hydrophobic amino 
Figure 3. Schematic representation of the domain structure of p53. The human p53 protein 
comprises several well-defined domains, including an N-terminal transactivation domain (TAD), followed 
by a central core DNA-binding domain, an oligomerization domain and a basic domain at the extreme C-
terminus. The p53 TAD is able to mediate p53 transcriptional activity and to regulate its stability through 
interaction with components of the transcription initiation complex, with co-activators, such as p300 and 
CBP, and with several regulatory proteins, such as MDM2 and MDMX. 
 
Figure 6. Regulation of cell cycle by p53, which transcriptional activation may lead to growth arrest 
at both G1 and G2 cell cycle phases. A) Under normal conditions the cyclin/Cdk complexes are 
functional and Rb family members are found hyperphosphorylated (yellow) leading to the release and 
activation of the E2F transcriptional factor and, consequently, to G1 progression. Under stress conditions 
(red arrows) p53 mediates the transcriptional induction of p21, which plays a pivotal role in mediating the 
arrest at G1-phase. p21 binds to, and inhibits, cyclin/Cdk complexes resulting in the accumulation of 
hypophosphorylated Rb (green) that interact with and inhibit E2F transcription factors activity. These 
results in an arrest at the G1-phase. B) p53 has also been implicated in the control of the G2/M checkpoint. 
Transcriptional down-regulation of cyclin B1 by p53 may be involved in p53-mediated G2 arrest, once that 
cyclin B1/Cdc2 complex is the major regulatory factor required for entry into mitosis. p53 is able to control 
G2 arrest by inhibition of Cdc25C and CAK, both required for activation of cyclin B1/Cdc2 complex. CAK 
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acids in its N-terminus: Leu22, Trp23, Trp53, and Phe54. When these four residues are 
mutated, the transactivation capability of p53 is completely abolished. The p53 TAD is 
involved in the p53 transcriptional activity and in the regulation of its stability. Both of these 
capabilities of the TAD are mediated through interaction with components of the 
transcription initiation complex, with acetyltransferases p300 and CBP (which act as co-
activators of p53), and with several regulatory proteins, such as MDM2 and MDMX. Actually, 
in unstressed cells, p53 would be kept at low levels essentially due to the action of MDMs, 
which inhibit its transcriptional activity (Figure 3). Upon stress, the N-terminus of p53 may 
suffer modifications that lead to the disruption of its contacts with MDMs. Therefore, p53 
can interact with transcriptional co-activators, that leads to modifications, such as 
acetylation in the C-terminus, and allows transcriptional activation and induction of different 
cellular responses (Figure 3) [reviewed in (Freed-Pastor and Prives, 2012; Joerger and 
Fersht, 2007)]. Although its precise function has not yet been clearly defined, the proline-
rich domain seems to be involved in growth suppression and apoptosis and its deletion 
results in a complete loss of this function (Sakamuro et al., 1997; Walker and Levine, 1996). 
Besides that, it is involved in p53 stabilization regulated by MDM2, since p53 becomes more 
susceptible to degradation if this region is deleted. It has also been reported that this domain 
comprises a negative auto-regulatory domain reducing the DNA-binding ability (Muller-
Tiemann et al., 1998). 
The DBD is responsible for the binding to sequence-specific DNA elements, located close 
to promoters of the p53 target genes. Indeed, this ability of p53 to bind to sequence-specific 
DNA elements is tightly linked to its pro-apoptotic activity [reviewed in (Ozaki et al., 2013)]. 
The C-terminal domain contains an oligomerization domain, involved in the ability of p53 to 
form active tetramers, followed by a basic domain, that interacts directly with single strands 
DNA (Figure 3) [reviewed in (Millau et al., 2009)].The basic domain of p53, acts as a flexible 
linker region that connects the DBD and the C-terminus of p53 (Cho et al., 1994). Besides 
that, the basic region of the C-terminus, which contains acetylation sites that binds DNA 
non-specifically, acts as a negative regulatory domain, and has been implicated in the 
induction of cell death [reviewed in (Joerger and Fersht, 2007)]. 
Interestingly, p63 and p73 share a significant homology with each other and with p53, 
having the same modular organization, which comprises an N-terminal TAD, a DBD and a 
C-terminal oligomerization domain and, consequently, similar functions (Strano et al., 
2002). 
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1.3.1 The p53 role in cell cycle regulation 
One of the most important cellular processes regulated by p53 is the cell cycle progression. 
This process consists on a series of steps at which the cell checks for the accuracy of the 
process and instructs itself to proceed to the next step. Cell cycle consists in a G1-phase, 
in which cells increase in size, in a S-phase, where the DNA is duplicated, in a G2-phase, 
in which cells continue to grow, and in a mitotic phase (M-phase), where chromosome 
segregation and cells division occurs. The G1 and G2 phases also provide the cell more 
time to grow and to ensure that the conditions are suitable for entry into the S-phase or 
mitosis [reviewed in (Nurse, 2000)]. 
The cell cycle is tightly regulated by stimulators and inhibitors containing intrinsic checkpoint 
controls, preventing in this way the transmission of damaged genetic material to the 
daughter cells and the consequent replication of abnormal material. Thus, there are three 
cell cycle checkpoints that regulate cells progression through each stage: the G1/S, the 
intra-S and the G2/M checkpoints. In case of DNA damage, the G1 checkpoint will lead to 
cell cycle arrest, ensuring that the DNA is not replicated during the S-phase. In response to 
damaged and/or un-replicated DNA the G2 checkpoint leads to cell cycle arrest 
safeguarding the proper completion of S-phase. The M-checkpoint leads to the arrest of 
chromosomal segregation in response to misalignment on the Mitotic spindle [reviewed in 
(Morgan, 1995)]. 
The cell cycle checkpoints are regulated by cyclin-dependent kinase (Cdk) complexes 
formed through association of a Cdk and a regulatory protein, a cyclin, that controls and 
activates the Cdk and whose levels change in a cyclical manner. So, since Cdk levels are 
usually constant throughout the cell cycle, its regulation and progression depends on 
variations of the levels of each cyclin (Sheaff et al., 1997). These cyclin/Cdk complexes 
regulate the phosphorylation of proteins involved in cell cycle progression, leading to DNA 
replication and mitosis. There are two types of cyclin/Cdks that regulate the transit of 
mammalian cells from quiescence into S-phase: the cyclin D, which activate Cdk4/6, and 
the cyclin E, which activates Cdk2 (Figure 4A) [reviewed in (Sherr and Roberts, 1999)]. 
Depending on the type of the cellular stress, the p53-mediated cell cycle arrest may be 
considered the primordial response to DNA damage. Actually, in response to a variety of 
stress conditions, such as chemotherapeutic treatments, p53 can trigger protective, pro-
survival responses, such as a temporary cell cycle arrest at the G1-phase, regulation of the 
G2/M transition, DNA repair and antioxidant protein production to maintain the genome 
integrity and the viability of cells that sustain limited reparable damage. All this is possible 
due to the ability of p53 to up-regulate the expression of several cell cycle proteins, such as 
GADD45 (Growth arrest and DNA damage protein 45), Cdc25C (Cell division cycle 25C) 
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and p21 (cdk inhibitor also known as CIP1/WAF1) (Figure 4A and B) [(Amundson et al., 
1998; El-Deiry, 1998); reviewed in (Nag et al., 2013)]. 
 
 
 
Figure 4. Regulation of cell cycle by p53, which transcriptional activation may lead to growth 
arrest at both G1 and G2 cell cycle phases. A) Under normal conditions the cyclin/Cdk complexes are 
functional and Rb family members are found hyperphosphorylated (yellow) leading to the release and 
activation of the E2F transcriptional factor and, consequently, to G1 progression. Under stress conditions 
(red arrows) p53 mediates the transcriptional induction of p21, which plays a pivotal role in mediating the 
arrest at G1-phase. p21 binds to, and inhibits, cyclin/Cdk complexes resulting in the accumulation of 
hypophosphorylated Rb (green) that interact with and inhibit E2F transcription factors activity. These 
results in an arrest at the G1-phase. B) p53 has also been implicated in the control of the G2/M 
checkpoint. Transcriptional down-regulation of cyclin B1 by p53 may be involved in p53-mediated G2 
arrest, once that cyclin B1/Cdc2 complex is the major regulatory factor required for entry into mitosis. p53 
is able to control G2 arrest by inhibition of Cdc25C and CAK, both required for activation of cyclin B1/Cdc2 
complex. CAK can be inhibited by p21 and Cdc25C by phosphorylation after activation of the Chk1 and 
Chk2 kinases, establishing a bind site to 14-3-3σ (green) proteins and leading to inactivation of Cdc2 
activity. Besides that, the progression into the M-phase requires Cdc2 which can be inhibited by 
overexpression of p21, GADD45 or 14.3.3σ, being the expression of these inhibitory proteins regulated 
by p53 in order to induce growth arrest. p53 has also other targets that do not affect cyclin B1/Cdc2 
complex but contribute to G2 arrest, namely Reprimo, B99 and poly(rC) binding protein 4 (PCBP4); P – 
phosphorylation; All the red arrows and crosses correspond to the p53 effect on cell cycle progression. 
 
Figure 8. Regulation of cell cycle by p53, which transcriptional activation may lead to growth 
arrest at both G1 and G2 cell cycle phases. A) Under normal conditions the cyclin/Cdk complexes are 
functional and Rb family members are found hyperphosphorylated (yellow) leading to the release and 
activation of the E2F transcriptional factor and, consequently, to G1 progression. Under stress conditions 
(red arrows) p53 mediates the transcriptional induction of p21, which plays a pivotal role in mediating the 
arrest at G1-phase. p21 binds to, and inhibits, cyclin/Cdk complexes resulting in the accumulation of 
hypophosphorylated Rb (green) that interact with and inhibit E2F transcription factors activity. These 
results in an arrest at the G1-phase. B) p53 has also been implicated in the control of the G2/M 
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During the G1-phase, the expression of cyclin D is stimulated, forming cyclin D/Cdk4/6 
complexes that phosphorylate the retinoblastoma (Rb) protein. Under normal conditions, 
the exit from G1 to S-phase requires the phosphorylation of Rb protein by cyclin/Cdk 
complexes. This results in the activation of the S-phase-promoting E2F transcription factor    
(required for entry into the S-phase), which binds to hypophosphorylated Rb protein (Figure 
4A) (Amundson et al., 1998; Chellappan et al., 1991). One of the target genes of E2F is 
cyclin E, which forms a complex with Cdk2 that phosphorylates and consequently inhibits 
the Rb protein, leading to DNA replication and progression though cell cycle (Koff et al., 
1992). Under stress conditions, p53 induces the transcriptional activation of p21 (major 
effector of G1 arrest), which in turn inactivates the cyclin/Cdk complexes. This enables the 
activation of Rb proteins and leads to the inhibition of E2F transcription factors (Figure 4A) 
(El-Deiry, 1998). 
The p53 protein is able to regulate the G2/M transition, blocking cell entry into mitosis by 
inhibition of Cdc2 (Cdk1), which needs to bind to cyclin B1 in order to be functional. Thus, 
the repression of cyclin B1/Cdc2 complex by p53 leads to an arrest in G2/M transition 
(Figure 4B) [reviewed in (Suzuki and Matsubara, 2011)]. Additionally, the biochemical 
pathways involved in the DNA damage-induced G2 arrest involve signalling cascades that 
converge to inhibit the activation of Cdc2. Therefore, p53 impacts the G2/M checkpoint by 
transcriptional modulation of the expression of multiple, physically and functionally 
intertwined targets, including Cdc25C, 14-3-3σ, p21, and GADD45 (Figure 4B) (El-Deiry, 
1998; Giono and Manfredi, 2006; Zhan et al., 1998). Mechanistically, p53 leads to G2/M 
arrest by repressing Cdc25C, a mitosis promoting phosphatase, which dephosphorylates 
and activates the cyclin B1/Cdc2 complex. In addition, the Cdc25C activity can be inhibited 
via phosphorylation by checkpoint kinases, Chk1 and Chk2, which, in turn, generate a 
consensus binding site for 14-3-3σ proteins. Binding of 14-3-3σ protein to Cdc25C results 
in the nuclear export of Cdc25C, sequestration of the phosphatase in the cytoplasm and, 
consequent inhibition of Cdc25C (Figure 4B) [reviewed in (Taylor and Stark, 2001)]. 
Besides the activity of Cdc25C, the Cdk-activating kinase (CAK) phosphorylates specific 
amino acid residues required for the activation of the cyclin B1/Cdc2 complex [reviewed in 
(Kishimoto and Okumura, 1997; Sherr and Roberts, 1999)]. Interestingly, some studies 
suggest that p21, involved in G1 arrest, is also implicated in G2 arrest by disruption of cyclin 
B1/Cdc2 complex through CAK (Figure 4B) (Smits et al., 2000; Zhan et al., 1999). 
The p53 protein has been reported to transcriptionally activate GADD45, which dissociates 
cyclin B1/Cdc2 complex by binding to Cdc2 [reviewed in (Taylor and Stark, 2001). This 
prevents the formation of the protein complex necessary for entry into the M-phase, 
resulting in G2 arrest (Zhan et al., 1999). p53 can also induce the expression of other 
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proteins involved in G2 arrest, namely Reprimo (a glycosylated, cytoplasmic protein that 
plays a role in cyclin B1/Cdk1 localization), B99 (a protein that may cause G2 arrest 
independently of Cdc2) [reviewed in (Taylor and Stark, 2001)] and poly(rC) binding protein 
4, a RNA-binding protein (Zhu and Chen, 2000) (Figure 4B). 
 
1.3.2 Apoptosis regulation by p53 protein 
Apoptosis is an evolutionary conserved and genetically controlled process of cell death that 
is essential, not only for development and maintenance of tissue homeostasis, but also for 
the elimination of unwanted cells during normal development and as a component of 
multistep carcinogenesis and therapy treatment resistance [reviewed in (Amaral et al., 
2010)]. This cellular mechanism is induced by a tightly regulated suicide programme 
characterized by several hallmarks as cell shrinkage, condensation and fragmentation of 
nuclear chromatin, DNA fragmentation, mitochondrial swelling and membrane blebbing as 
well as by loss of mitochondrial membrane integrity. This mechanism of cell death is 
considered very “clean” occurring without stimulation of an inflammatory response 
[reviewed in (MacFarlane, 2003; Sharp et al., 2010)]. 
Alteration of many proteins involved in the apoptotic signalling pathways have been 
described and it is clear that alterations of upstream regulators of these pathways are the 
most common alterations found in cancer cells. As an example p53, that can induce cell 
death in response to a number of different stress stimuli, regulates the expression of a wide 
variety of genes involved in apoptosis [reviewed in (Vaseva and Moll, 2009)]. The apoptotic 
function of p53 has been first reported in mouse thymocytes, in response to irradiation 
(Clarke et al., 1993; Lowe et al., 1993). Since then, the p53-dependent apoptosis has been 
reported in a wide range of cells in response to many different stress signals [reviewed in 
(Amaral et al., 2010)]. 
p53 stimulates a wide network of signals that can act through two major apoptotic pathways 
(Figure 5): the extrinsic (or death receptor) and the intrinsic (or mitochondrial) [reviewed in 
(Amaral et al., 2010; MacFarlane, 2003)]. The apoptotic extrinsic pathway is triggered by 
extracellular signals that result in the binding of ligands to specific trans-membrane death 
receptors located at the plasma membrane, such as KILLER/DR5 and Fas (also called 
APO-1). Fas is a member of the tumour necrosis factor receptor (TNFR) superfamily and, 
in turn, KILLER/DR5 is a member of the TNF-related apoptosis-inducing ligand (TRAIL) 
family of death receptors [reviewed in (Ashkenazi and Dixit, 1998; Haupt et al., 2003; Sharp 
et al., 2010)]. The activation of these receptors, after binding to their ligands, leads to their 
trimerization and consequent clustering of the intracellular death domain, which 
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subsequently recruits the protein adaptor FADD (Fas-associated protein with death domain) 
through homotypic death domain interactions. The death effector domain of FADD then 
recruits procaspase-8 forming the death-inducing signalling complex (DISC) (Yu et al., 
2001). The formation of the DISC complex results in caspase-8 activation and consequently 
in executioner caspases activation (Figure 5A), resulting in DNA fragmentation as an 
hallmark of apoptosis [reviewed in (Schuler and Green, 2001)]. The p53 overexpression 
enhances cell surface levels of Fas by promoting its trafficking from Golgi complex. Thus, 
p53 status may influence the chemosensitivity via Fas signalling [reviewed in (Suzuki and 
Matsubara, 2011)] and activate KILLER/DR5, which is induced in response to DNA damage 
and, consequently, promote cell death through caspase-8 activation (Liedtke et al., 2003) 
(Figure 5A). 
On the other hand, the intrinsic apoptotic pathway can be activated in response to a variety 
of cellular insults or other damaged signals such as radiation. This apoptotic pathway is 
regulated by members of the Bcl-2 family and involves the disruption of mitochondrial 
membrane integrity and subsequent release of apoptogenic proteins from the mitochondria 
into the cytosol (Voortman et al., 2007). The disruption of mitochondrial membrane integrity 
results in biochemical and structural changes of mitochondria including mitochondrial 
swelling, changes at the mitochondrial outer membrane permeabilization (MOMP), loss of 
mitochondrial membrane potential (∆ψm), and cytochrome c (cyt c) release (Figure 5B). 
Actually, it has been proposed that mitochondrial depolarization defines an early and 
irreversible stage of apoptosis preceding other manifestations in this process, such as DNA 
fragmentation and reactive oxygen species (ROS) production. Additionally, the increase of 
∆ψm is often observed in human cancer cells (Li et al., 1998; Vrablic et al., 2001; Zamzami 
et al., 1995). 
Therefore, MOMP is essential for the regulation of the apoptotic process and the proteins 
of the Bcl-2 family are the main regulators of this deadly switch (Renault et al., 2013). The 
members of the Bcl-2 family include anti-apoptotic, such as Bcl-2 and Bcl-xL, and pro-
apoptotic proteins, such as Bax, Bak, Bid, NOXA and PUMA (p53 Up-regulated Modulator 
of Apoptosis), that can be classified on basis of structural similarity to the BH (Bcl-2 
Homology) domains (BH1, BH2, BH3 and BH4) and a transmembrane domain, being the 
BH3 domain crucial for the pro-apoptotic function [reviewed in (Amaral et al., 2010; Igney 
and Krammer, 2002; Manfredi, 2003)]. Bax and Bak are the direct pro-apoptotic effectors 
of MOMP as they can translocate and/or insert into the outer mitochondrial membrane, 
oligomerize and form pores, leading consequently to cyt c release. Despite Bax and Bak 
are functionally redundant proteins, Bak has a constitutive mitochondrial localization in 
healthy cells, whereas Bax is mostly cytosolic, awaiting for activation signals that will trigger 
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its translocation to mitochondria and further activation (Figure 5B) (Renault et al., 2013). 
Bax activation is favoured by the pro-apoptotic BH3-only proteins, who can act both as 
direct activators of Bax (tBid, Bim, PUMA), by interacting directly with him, or as 
derepressors (Bad and Noxa), by interacting with anti-apoptotic members of the Bcl-2 
family. The anti-apoptotic family members bind the BH3 domains of pro-apoptotic family 
proteins, preventing Bak/Bax homo-oligomerization and BH3-only proteins activation. The 
overexpression of anti-apoptotic members has been reported in most human cancers, 
favouring survival of neoplastic cells and consequently the resistance to chemotherapeutic 
agents [(Gallenne et al., 2009; Renault et al., 2013); reviewed in (Vaseva and Moll, 2009)]. 
Curiously, the binding region for Bcl-xL and Bcl-2 on p53 is located in the DBD, the same 
region that harbours the vast majority of “hotspot” mutations found in human cancers. 
Indeed, it was shown that such mut p53 proteins are defective in their ability to interact with 
Bcl-xL and Bcl-2 family of proteins (Mihara et al., 2003). 
After several studies, it is clearly established that in response to a stress signal, cytoplasmic 
p53 rapidly translocates to mitochondria, where it can promote apoptosis in a 
transcriptional-independent manner, preceding the loss of ∆ψm (Mihara et al., 2003). At the 
mitochondria, p53 is able to interact, either to inhibit or activate, with several anti- and pro-
apoptotic genes of the Bcl-2 family, such as Bcl-2, BAX, NOXA, PUMA and BID (BH3-only 
proteins). Indeed, by directly interact with the anti-apoptotic proteins Bcl-xL and Bcl-2, p53 
is able to inhibit these proteins inducing cyt c release [reviewed in (Amaral et al., 2010; 
Igney and Krammer, 2002; Manfredi, 2003; Vaseva and Moll, 2009)]. These interplay 
between pro- and anti-apoptotic members of the Bcl-2 family, after p53 activation, has been 
found to control the MOMP, and consequently the cyt c release from the mitochondria 
intermembrane space into the cytosol, unleashing the activation of the apoptotic machinery 
of caspases, chromatin degradation and apoptosis (Figure 5B) (Xiao et al., 2005). Once in 
the cytosol, cyt c participates in the formation of the apoptosome complex together with its 
adaptor molecule, Apaf-1 (Apoptotic Protease-Activating Factor-1), which activates 
procaspase-9 and promotes activation and cleavage of executioner caspases (procaspase-
3, -6 and -7) (Figure 5B). This event leads to the cleavage of other specific death substrates, 
cellular and nuclear morphological changes, and ultimately, to cell death (Li et al., 1998). 
Thus, it is logical to assume that cyt c release is the rate-limiting step in initiating the caspase 
activation cascade and the main consequence of p53-mediated signals leading to apoptosis 
(Shinoura et al., 2001). Additionally, PUMA may play a pivotal role in determining cell fate 
(programmed cell death versus cell cycle arrest) in response to p53 activation, being an 
essential mediator for p53-dependent  apoptosis in vivo (He et al., 2013). 
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Interestingly, there are evidences that the two apoptotic pathways are not exclusive. 
Instead, they can be linked and molecules in one pathway can influence the other. In fact, 
both pathways activate caspases, proteolytic enzymes functionally divided into two groups 
(initiator and executioner) that carry out apoptotic cell death. Once initiator caspases (such 
Figure 5. Schematic representation of the regulation of intrinsic and extrinsic apoptotic pathways 
by p53. The p53 protein is able to induce transcription of proteins involved in both apoptotic pathways. 
A) In the extrinsic pathway, the binding of ligands to specific trans-membrane death receptors (Fas and 
KILLER), leads to the recruitment of the adaptor molecule, FADD. Then, the procaspase-8 binds to FADD 
leading to DISC formation and resulting in caspase-8 activation. Activated caspase-8 directly activates 
executioner caspases (caspase-3, -6, and -7) or cleaves the pro-apoptotic protein Bid. B) In the 
intrinsic/mitochondrial pathway the stress-induced mitochondrial translocation of p53 results in 
interactions between several anti- and pro-apoptotic members of the Bcl-2 family in order to induce 
MOMP and cyt c release. Indeed, p53 interacts with Bcl-xL/Bcl-2 blocking their inhibitory effect on pro-
apoptotic Bax. Besides that it is able to activate genes such as PUMA and NOXA, which binds to and 
inhibit the activity of the anti-apoptotic proteins Bcl-2/Bcl-XL, unleashing the translocation of cytosolic Bax 
to the mitochondria. This leads to mitochondrial permeabilization and activation. The release of cyt c from 
the mitochondria results in the formation of the apoptosome and caspase-9 activation. Then, both 
caspase-8 and -9 activate executioner caspases, namely caspases-3, -6 and -7, resulting in cell death. 
Additionally, the MOMP can lead to a loss of the ∆ψm and to increase ROS production [adapted from 
(Haupt et al., 2003)]. 
 
Figure 10. Schematic representation of the primary structure of MDM2 and MDMX proteins. Both 
MDM2 and MDMX proteins comprises a p53-bindi g domain, an cidic and a zi -finger domain i  their 
central portion followed by a C-terminal Ring-finger domain. Additionally, the MDM2 protein possess a 
nuclear localization signal (NLS) and a nuclear export signal (NES) sequence.Figure 11. Schematic 
represent tion of the regulation of intrinsic and extrinsic apoptotic pathw ys by p53. The p53 
protein is able to induce transcription of proteins involved in both apoptotic pathways. A) In the extrinsic 
pathway, the binding of ligands to specific trans-membrane death receptors (Fas and KILLER), leads to 
the recruitment of the adaptor molecule, FADD. Then, the procaspase-8 binds to FADD leading to DISC 
formation and resulting in caspase-8 activation. Activated caspase-8 directly activates executioner 
caspases (caspase-3, -6, and -7) or cleaves the pro-apoptotic protein Bid. B) In the intrinsic/mitochondrial 
pathway the stress-induced mitochondrial translocation of p53 results in interactions between several 
anti- and pro-apoptotic members of the Bcl-2 family in order to induce MOMP and cyt c release. Indeed, 
Extrinsic Pathway (A)  
Intrinsic Pathway (B) 
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as caspases-8, -9 and -10) are activated, they cleave and activate (directly or indirectly) 
executioner caspases (such as caspase-3, -6 and -7) that, in turn, cleave intracellular 
substrates, such as poly(ADP-ribose)polymerase (PARP) (Figure 5A and B), leading to 
biochemical and morphological changes that are characteristics of apoptosis. This makes 
the activation of initiator caspases a key step to cell death [reviewed in (Igney and Krammer, 
2002; MacFarlane, 2003)]. One of the major links between the two pathways is provided by 
the pro-apoptotic Bcl-2 family member Bid. Activation of Bid can promote MOMP and 
involves cleavage of cytoplasmic Bid by caspase-8 to expose a new N-terminal glycine 
residue that is subsequently myristoylated. Myristoylated Bid translocates to the 
mitochondria, inserts into the membrane and activates Bax and Bak to initiate mitochondrial 
events leading to apoptosome formation. The BID gene is transcriptionally regulated by p53 
in response to -irradiation. Therefore, p53 appears to promote the convergence of the 
intrinsic and extrinsic pathways through Bid regulation (Li et al., 1998; Zha et al., 2000). 
Finally, increased mitochondrial production of ROS, has been related to the loss of ∆ψm, in 
cancer cells, but not in normal cells (Gogvadze et al., 2008). While normal levels of ROS 
can be pro-proliferative, excess of ROS production can damage DNA and proteins, 
contributing to the development of various diseases (Maddocks and Vousden, 2011).  
Interestingly, it was showed that p53 protects cells from oxidation by reducing the 
production of intracellular ROS (Bensaad et al., 2006). Although ROS are by-products of 
normal mitochondrial function, high levels of ROS have been associated with p53-induced 
apoptosis (Figure 5B). The p53 deficiency in cells and mouse tissues results in the elevation 
of intracellular ROS levels, which in turn leads to the increased DNA oxidation and mutation 
rates in cells (Budanov et al., 2004; Sablina et al., 2005). 
 
1.4  Endogenous negative regulators of p53: MDM2 and MDMX 
Under normal conditions, p53 remains at low levels due to its short half-life allowing normal 
cell proliferation and viability. However, in response to cellular stresses, p53 becomes 
stabilized and modulates the transcription of target genes. As referred above, in tumours in 
which p53 is not mutated, its function is inhibited by overexpression of its two major negative 
regulators MDM2 and MDMX. Actually, both of them regulate the p53 activity by inhibiting 
its transcriptional activity (Jones et al., 1995; Parant et al., 2001). 
The MDM2 gene encodes a protein that was first described in the late 1980s as an amplified 
gene responsible for the spontaneous transformation of an immortalized murine cell line, 
BALB/c 3T3 (Cahilly-Snyder et al., 1987). Within 5 years, the oncogenic potential of MDM2 
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gene was demonstrated, with several studies showing that MDM2 interacts directly with p53 
and inhibits its ability to function as a transcriptional activator [reviewed in (Manfredi, 2010)]. 
In the middle 90s, a screen for p53-binding proteins led to the identification of a protein 
sharing a structural homology with MDM2. This protein was first called MDMX and later 
given the official name of MDM4. The high level of structural similarity makes us thought 
that these two proteins derived from the duplication of a single ancestral gene [reviewed in 
(Toledo and Wahl, 2006; Toledo and Wahl, 2007)]. 
The MDM2 gene is overexpressed in a wide range of human cancers expressing wt p53 
including breast carcinomas, glioblastomas and sarcomas, whereas overexpression of 
MDMX can be detected in melanomas, retinoblastomas and breast carcinomas, being both 
associated with resistance to treatment, poor prognosis, metastasis and advanced forms of 
the disease [reviewed in (Nag et al., 2013)]. 
The full-length transcripts of MDM2 and MDMX genes encode structural related proteins of 
491 and 400 amino acids, respectively (Figure 6). Thus, both MDMs bind to a short α-helical 
stretch on the p53 TAD domain through their N-terminal hydrophobic region, which is the 
best conserved region between the two proteins [reviewed in (Toledo and Wahl, 2007; 
Wang and Jiang, 2012)]. By blocking the p53 TAD domain and occupying the binding site 
of co-activators, such as p300 [reviewed in (Hock and Vousden, 2014)], these proteins lead 
to the inhibition of the p53 transcriptional function (Kussie et al., 1996; Momand et al., 1992). 
Both MDM2 and MDMX possess a zinc-finger domain together with a central acidic domain, 
followed by a C-terminal RING-finger domain, with this last domain receiving special 
attention for its multiple functions (Fang et al., 2000). Additionally, only MDM2 possesses a 
nuclear localization signal (NLS) and a nuclear export signal (NES), responsible for shuttling 
MDM2 between the nucleus and the cytoplasm (Figure 6). This suggests that MDM2 binds 
to p53 in the nucleus and transports it to the cytoplasm for ubiquitin-mediated degradation 
by the proteasome [reviewed in (Freedman et al., 1999)] (Figure 7). 
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Several studies have reported the distinct but complementary roles of MDM2 and MDMX in 
p53 regulation. Indeed, although both proteins inhibit the p53 transcriptional activity, they 
have significant differences in their p53 regulation mechanisms. Previous in vivo studies 
confirmed the separated importance of this two proteins indicating that while MDM2 mainly 
regulates p53 stability, MDMX has a major role in regulating its activity [reviewed in (Toledo 
and Wahl, 2006; Toledo and Wahl, 2007; Vassilev, 2007)]. Interestingly, although the RING-
finger domains of MDM2 and MDMX share a high level of homology, only MDM2 possess 
the ability to act as an E3 ubiquitin ligase, leading p53 and itself for degradation by 
ubiquitination (Marine and Jochemsen, 2005), whereas MDMX controls the levels of p53 by 
modulating the levels of MDM2 (Linke et al., 2008). Several studies, have shown that MDM2 
and MDMX function in a non-overlapping manner, creating a negative feedback loop, which 
precisely controls the level and activity of p53 [reviewed in (Lenos and Jochemsen, 2011; 
Popowicz et al., 2011; Shadfan et al., 2012; Vassilev, 2007)]. Additionally, if in one way the 
endogenous negative regulators of p53 are able to inhibit and regulate its expression levels, 
p53 has shown to be capable to induce the transcription of both MDM2 [reviewed in 
Figure 6. Schematic representation of the primary structure of MDM2 and MDMX proteins. Both 
MDM2 and MDMX proteins comprises a p53-binding domain, an acidic and a zinc-finger domain in their 
central portion followed by a C-terminal Ring-finger domain. Additionally, the MDM2 protein possess a 
nuclear localization signal (NLS) and a nuclear export signal (NES) sequence.  
 
Figure 12. Regulation of p53 by its negative regulators MDM2 and MDMX. In normal cells, p53 
increases the MDM2 and MDMX transcription over basal levels (red arrows). MDM2 and MDMX cooperate 
to inhibit the p53 function by modulating its transcriptional activity and by preventing its interaction with the 
general transcription machinery. As a homodimer, MDM2 is able to promote p53 nuclear export to the 
cytoplasm for ubiquitin-mediated degradation by the proteasome. Additionally, MDM2 can also form a 
heterodimeric complex with MDMX promoting the nuclear degradation of p53 (polyubiquitination) and 
MDMX ubiquitination by MDM2. These cellular mechanisms result in subtle control of p53 levels; (Ub: 
ubiquitin)Figure 13. Schematic representation of the primary structure of MDM2 and MDMX proteins. 
Both MDM2 and MDMX proteins comprises a p53-binding domain, an acidic and a zinc-finger domain in 
their central portion followed by a C-terminal Ring-finger domain. Additionally, the MDM2 protein possess 
a nuclear localization signal (NLS) and a nuclear export signal (NES) sequence.  
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(Manfredi, 2010)] and MDMX proteins (Li et al., 2010), thus establishing a negative 
feedback loop (Figure 7). 
 
 
 
It has been described that, under normal conditions, MDM2 is able to inhibit the p53 activity 
through ubiquitination, either in the form of a homodimer or of a heterodimer, being the 
RING-finger domains integrity essential for these hetero or homodimerization (Lenos and 
Jochemsen, 2011; Linke et al., 2008). This complex results in the stabilization of MDM2 
and, consequently, the ability of MDM2 to monoubiquitinate or polyubiquitinate p53 depends 
on its expression levels (Li et al., 2003). In fact, when the levels of MDM2 are low, 
monoubiquitination of p53 promotes the export of p53 from the nucleus to the cytoplasm 
Figure 7. Regulation of p53 by its negative regulators MDM2 and MDMX. In normal cells, p53 
increases the MDM2 and MDMX transcription over basal levels (red arrows). MDM2 and MDMX cooperate 
to inhibit the p53 function by modulating its transcriptional activity and by preventing its interaction with 
the general transcription machinery. As a homodimer, MDM2 is able to promote p53 nuclear export to the 
cytoplasm for ubiquitin-mediated degradation by the proteasome. Additionally, MDM2 can also form a 
heterodimeric complex with MDMX promoting the nuclear degradation of p53 (polyubiquitination) and 
MDMX ubiquitination by MDM2. These cellular mechanisms result in subtle control of p53 levels; (Ub: 
ubiquitin) 
 
 
Figure 14. Schematic representation of small molecule inhibitors of MDM proteins. Isoindolinones, 
cis-imidazolines, xanthones, oxazoloi oi dolinones, among others, act as inhibitors of the p53-MDM2 
interaction. SJ-172550, benzofuroxan and pseudorea act as inhibitors of p53-MDMX interaction. The 
pyrrolopyrimidine-based small molecules and the compound RO-5963 from the Indolyl hydantoin chemical 
family, as shown to inhibit both p53-MDM2 and p53-MDMX in er ctions.Figure 15. Regulation of 53 by
its negative regulators MDM2 and MDMX. In normal cells, p53 increases the MDM2 and MDMX 
transcription over basal levels (red arrows). MDM2 and MDMX cooperate to inhibit the p53 function by 
dulating its transcriptional activity and by preven ing its interaction with the general transcription
machinery. As a homodimer, MDM2 is able to promote p53 nuclear export to the cytoplasm for ubiquitin-
mediated degradation by the proteasome. Additionally, MDM2 can also form a heterodimeric complex with 
MDMX promoting the nuclear degradation of p53 (polyubiquitination) and MDMX ubiquitination by MDM2. 
These cellular mechanisms result in subtle control of p53 levels; (Ub: ubiquitin) 
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and consequent inhibition of p53 transcriptional activity (Figure 7). Once in the cytoplasm, 
p53 can be further ubiquitinated and degraded by p300. However, processes such as 
apoptosis has been described to be positively regulated by a number of different functions 
of cytoplasmic p53 [reviewed in (Hock and Vousden, 2014)]. Instead, high levels of MDM2 
favour the p53 polyubiquitination, which results in the nuclear degradation of p53 (Figure 
7). This degradation mechanism is responsible for the maintenance of low p53 levels in 
unstressed cells (Li et al., 2003). 
Interestingly, the MDM2/X heterodimer complex induces polyubiquitination of p53, whereas 
MDM2 alone is primarily responsible for its monoubiquitination with further degradation of 
p53. Another consequence of MDMs heterodimerization is the MDMX ubiquitination (Figure 
7) (Linke et al., 2008). The MDM2/MDMX E3 ligase as well as p53 can be regulated by 
deubiquitinases. Indeed, the deubiquitination and stabilization of both MDM2 and MDMX by 
the ubiquitin-specific protease 7(USP7) plays a pivotal role in the control of p53 stability 
[reviewed in (Hock and Vousden, 2014; Wang and Jiang, 2012)]. 
Many currently used cancer therapies, such as chemotherapy and radiation, have been 
primarily focused on p53 reactivation to trigger an apoptotic response. Unfortunately, high 
doses of these genotoxic treatments can also induce p53-independent pathways and thus 
may cause severe toxicities in normal tissues, which could eventually lead to secondary 
malignancies. In this context, efforts have been made in order to develop new selective and 
nongenotoxic inhibitors of the p53-MDMs interactions as an alternative to conventional 
cytotoxic chemotherapy [reviewed in (Shangary and Wang, 2009; Tisato et al., 2013)]. In 
fact, over the past years, the concept of selective chemotherapy has dominated the field of 
drug discovery and development. In this regard, the pharmacological restoration of the 
impaired function of p53, by disrupting its interaction with MDMs proteins has been shown 
to be an alternative therapeutic strategy against a broad spectrum of cancers with wt p53. 
Besides, the combination of various drugs that target multiple p53 pathways may be a useful 
strategy to achieve synergistic drug efficacy by reducing the genotoxic burden with the 
same or better anti-tumour effect [reviewed in (Popowicz et al., 2011; Zhao et al., 2013a)].  
 
1.4.1 Inhibitors of MDM2 and MDMX in anticancer therapy 
Over the past years, it has been difficult to develop small molecule inhibitors that disrupt 
large protein-protein interactions. Despite all the difficulties, and few progresses made in 
the first years, small molecules have been developed that compete for the p53 binding site 
of MDM2, inhibiting the binding and degradation of p53 by MDM2. The disruption of the 
p53-MDM2 interaction has shown to restore the wt p53 activity and to drive cancer cells 
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selectively into apoptosis [reviewed in (Shangary and Wang, 2009)]. Several studies of 
small molecule inhibitors of p53-MDM2 interaction, carried out in different cancer cell lines 
and animal models, support their usefulness as potential anticancer agents in tumours with 
overexpression of MDM2 [reviewed in (Vassilev, 2007)]. 
Several classes of chemical families have been reported as potent inhibitors of the p53-
MDM2 interaction like the cis-imidazoline compounds, most commonly known by nutlins 
(Vassilev et al., 2004), the spiro-oxindoles (Zhao et al., 2013b), the isoindolinones 
(Hardcastle et al., 2011), the piperidinones (Rew et al., 2012), the xanthones (Leão et al., 
2013a; Leao et al., 2013) and the oxazoloisoindolinones (Soares et al., 2014b), among 
others (Figure 8). A common way of action of several compounds, like nutlins and spiro-
oxindoles, is mimicking the three pivotal amino acids that mediate the interaction of p53 
with MDM2: Phe19, Trp23 and Leu26, blocking the p53-MDM2 interaction (Zhao et al., 
2013a). However, only few inhibitors of the p53-MDM2 interaction have advanced into 
clinical trials [reviewed in (Hoe et al., 2014)] namely RG7112, an oral formulation of nutlin 
series (Ray-Coquard et al., 2012; Vassilev et al., 2004), and MI-773 (spiro-oxindole) (Hoe 
et al., 2014; Zhao et al., 2013b).  
Encouraged by the success in the design of small molecule inhibitors of the p53-MDM2 
interaction, efforts have been made towards the development of small molecule inhibitors 
of the p53-MDMX interaction, such as SJ-172550 (Reed et al., 2010). Interestingly, high 
levels of MDMX protein are known to confer resistance to MDM2 inhibitors, which have 
shown very low binding affinity to MDMX. In fact, the apoptotic response of some p53-
MDM2 interaction inhibitors, such as nutlin-3a, is markedly attenuated in MDMX-
overexpressing tumours, such as in retinoblastomas and melanomas [reviewed in (Hoe et 
al., 2014)]. Since the simultaneous inhibition of the p53-MDM2 and p53-MDMX interaction 
is required for a full reactivation of p53, efforts have been made for the development of dual 
inhibitors of MDM2 and MDMX. Actually, very few compounds with dual specificity against 
both MDM2 and MDMX, namely pyrrolopyrimidine-based small molecules (Lee et al., 2011) 
and RO-5963 from the Indolyl hydantoin chemical family (Graves et al., 2012), were 
reported. Being these two compounds the only dual inhibitors found to date, the search for 
new ones is highly required. 
ICBAS 
Drugging p53 in cancer 22 
 
 
 
Inhibitors of the interaction of p53 with MDM2 and MDMX may also be important in 
cyclotherapy, in order to protect normal proliferating cells during antimitotic chemotherapy 
and offering to the patient a reduction in the side effects without loss of efficacy [reviewed 
in (Hoe et al., 2014; Popowicz et al., 2011; Zhao et al., 2013a)]. In this way, the pre-
treatment with very low, non-genotoxic doses of MDM2/MDMX inhibitors will lead to cell 
cycle arrest in normal cells with functional p53, thus protecting them from the toxicity of the 
chemotherapy. This cytostatic effect of p53 can protect normal cells from the toxicity of S- 
or M-phase poisons. Conversely, tumour cells expressing mut p53, that will be insensitive 
to the MDM2 and MDMX inhibitors, will remain selectively vulnerable to the mitotic poison 
[reviewed in (Vassilev, 2007)]. One example of this applicability of MDM2 inhibitors was 
provided by Sur and colleagues, who showed in a mouse xenograft model that the 
neutropenia induced by the polo-like kinase 1 (PLK1) inhibitor, BI-2536, could be prevented 
by the prior exposure to nutlin-3a, reducing the toxicity associated with BI-2536. Importantly, 
this MDM2 inhibitor have no impact on the antitumour effect of this PLK1 inhibitor (Sur et 
al., 2009). 
Additionally, several recent studies have investigated the possible synergistic interactions 
between traditional drugs and nutlin-3a. Indeed, nutlin-3a combined with cisplatin, 
methotrexate or doxorubicin has been reported to induce apoptosis much more efficiently 
than either drug alone in cells with dysfunctional p53 pathways. Actually, nutlin-3a seemed 
Figure 8. Schematic representation of small molecule inhibitors of MDM proteins. Isoindolinones, 
cis-imidazolines, xanthones, oxazoloisoindolinones, among others, act as inhibitors of the p53-MDM2 
interaction. SJ-172550, benzofuroxan and pseudorea act as inhibitors of p53-MDMX interaction. The 
pyrrolopyrimidine-based small molecules and the compound RO-5963 from the Indolyl hydantoin chemical 
family, as shown to inhibit both p53-MDM2 and p53-MDMX interactions. 
Figure 16. Schematic representation of the prevalence of TP53 missense mutations in human 
cancers. The columns indicate the relative frequency of cancer-associated mutations for each residue 
according to the TP53 mutation database of The p53 Web Site [adapted from (Millau et al., 2009)].Figure 
17. Schematic representation of small molecule inhibitors of MDM proteins. Isoindolinones, cis-
imidazolines, xanthones, oxazoloisoindolinones, among others, act as inhibitors of the p53-MDM2 
interaction. SJ-172550, benzofuroxan and pseudorea act as inhibitors of p53-MDMX interaction. The 
pyrrolopyrimidine-based small molecules and the compound RO-5963 from the Indolyl hydantoin chemical 
family, as shown to inhibit both p53-MDM2 and p53-MDMX interactions. 
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to potentiate the effect of these drugs with simultaneous reduction of their cytotoxicity (Mir 
et al., 2013; Ohnstad et al., 2011). 
 
1.5 p53 mutant forms 
Mutations in TP53 allow tumour cells to subvert the biological meaning of the p53 pathway 
turning it into a tumour promoting network. It is important to recognize that not all p53 
mutants are equal, not merely as a conceptual distinction, but also for the practical 
implication. Nowadays the objective is to personalize cancer therapy as much as possible, 
so it is important not only to differentiate wt and mut p53, but also to ascertain the particular 
mutation that a patient´s tumour bears. Over the last years, p53 mutants have been found 
to actively contribute to tumour proliferation, survival, limitless replication, somatic cell 
reprogramming, genomic instability, inflammation, disruption of tissue architecture, 
migration, invasion, angiogenesis, and metastasis. Amazingly, this places mut p53 in a 
central role in tumourigenesis, impacting nearly all of the 10 cancer hallmarks (Figure 1) 
[reviewed in (Freed-Pastor and Prives, 2012; Girardini et al., 2014)]. 
The p53 function is almost always compromised in tumour cells, usually as a result of 
somatic mutations, which occurs in approximately half of all human cancers. Nevertheless, 
depending on the type of cancer, the frequency of TP53 mutations is highly variable ranging 
from less than 5% (in cervical carcinoma) to 90% (in ovarian carcinoma) [reviewed in (Leroy 
et al., 2014)]. 
Whereas somatic TP53 mutations contribute to sporadic cancer, germline mutations cause 
a rare type of cancer predisposition, known as Li–Fraumeni Syndrome. This unique 
syndrome, among cancer predispositions, results from an inherited point mutation in a 
conserved region of p53 and it is not associated with site-specific tumours, but rather with 
a variety of tumour types occurring at a relatively early age (Malkin et al., 1990; Srivastava 
et al., 1990). Importantly, both somatic and germline TP53 mutations are usually followed 
by loss of heterozygosity during tumour progression, which suggests that a selective force 
inactivates the remaining wt allele [reviewed in (Brosh and Rotter, 2009)]. 
Structural studies of p53 have revealed that the majority (around 75%) of p53 mutations 
found in human cancers are single amino acid substitutions (missense mutations). These 
missense mutations lead to the production of a mut protein that differs from the wt p53 by 
one amino acid, resulting in the formation of a full-length protein incapable of activate p53 
target genes and suppress tumourigenesis, and that consequently leads to an accumulation 
of mut p53 in human tumour cells [reviewed in (Brosh and Rotter, 2009; Freed-Pastor and 
Prives, 2012)].  
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Interestingly, the majority of these mutations occurs in the genomic region encoding the 
sequence-specific DBD of p53, leading to structural changes that destabilizes the p53 
structure and disrupt the proper conformation of the sequence-specific DBD. Therefore, 
these mutations can abrogate the sequence-specific transactivation ability of wt p53 
[reviewed in (Bassett et al., 2008; Ozaki et al., 2013)]. 
Although mutations have been found in almost every codon within the DBD of p53, only the 
most frequently occurring mutations have been deeply studied for their contribution to 
cancer progression. The existence of these hotspot residues can be explained both by the 
susceptibility of particular codons to carcinogen-induced alterations and by positive 
selection of mutations that render the cell more susceptible to growth and survival [reviewed 
in (Freed-Pastor and Prives, 2012; Muller and Vousden, 2014)]. In fact, TP53 mutations in 
cancer affect manly six “hotspot” residues within the DBD, namely the residues R175, G245, 
R248, R249, R273 and R282 [reviewed in (Muller and Vousden, 2014; Ozaki et al., 2013)]. 
Furthermore, there are two other residues of p53 with a significant mutation incidence, 
namely Y220 and R280 (Soussi and Béroud, 2012) (Figure 9). For their relevance at the 
present work, mutations at residues R175, Y220, R273 and R280 will be described in 
greater detail. 
 
 
Figure 9. Schematic representation of the prevalence of TP53 missense mutations in human 
cancers. The columns indicate the relative frequency of cancer-associated mutations for each residue 
according to the TP53 mutation database of The p53 Web Site [adapted from (Millau et al., 2009)]. 
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A well-established classiﬁcation system for mut p53 is based on its role as a transcriptional 
factor. Thus, according to the effect of the amino acid substitution, p53 mutants can 
generally be classified into two main categories: ‘‘conformational / structural’’ or ‘‘DNA 
contact’’ mutants. Both types are missense mutations that prevent the pro-apoptotic p53 
transactivation functions by blocking the binding of p53 with target promoter sites on DNA. 
The DNA contact mutants [such as p53 R273H and p53 R280K (Cho et al., 1994)] prevent 
the wt transcriptional activity without dramatically affecting the conformation of p53 protein. 
However, the majority of mut p53 proteins found in human tumours are structural mutants 
[p53 R175H (Cho et al., 1994) and p53 Y220C (Boeckler et al., 2008)] that disrupt the 
structure of the p53 protein, on either a local or global level (Liu et al., 2013; Yu et al., 2012). 
These missense mutations usually confer to the mut protein a dominant-negative activity 
over the remaining wt allele, in this way, when wt and mut p53 alleles exist in a heterozygous 
status in tumour cells, mut p53 can block the function of wt p53 (Figure 10). Mutant proteins 
usually accumulate in large amounts in cancer cells, which is partially explained by a loss 
of the wt p53 function, including a loss of the ability to induce the transcriptional activation 
of its negative regulator MDM2 [reviewed in (Brosh and Rotter, 2009)] (Figure 10). 
Interestingly, it has been well-documented that some tumour-associated mut p53 not only 
lose the tumour suppressive function of wt p53 and acquire dominant-negative activities, 
but also gain new oncogenic functions that are entirely independent of wt p53, referred as 
the gain-of-function (GOF) (Figure 10) [reviewed in (Bassett et al., 2008; Girardini et al., 
2014)]. Thus, the GOF of mut p53 can contribute to the close correlation between the 
expression of mut p53 and the higher frequency of tumour development, chemoresistance, 
angiogenesis, migration, increased invasive and metastatic potential and poor prognosis of 
cancer patients  [reviewed in (Freed-Pastor and Prives, 2012)]. Indeed, previous studies 
have proposed that acquisition of oncogenic GOF activities, were clearly demonstrated in 
two mut p53 knock-in mouse models of Li-Fraumeni syndrome. These models have 
reported evidence of GOF for R175H and R273H mutants (Lang et al., 2004; Olive et al., 
2004). Recent data suggests that the activity of p53 GOF mutants may also be mediated 
by inhibitory interactions with other transcriptional factors that normally bind to gene 
promoters [reviewed in (Song and Xu, 2007; Xu, 2008)]. An important example is the 
interaction of such p53 mutants with the family members p63 and p73 [reviewed in (Brosh 
and Rotter, 2009)].  
Interestingly the core domain of p53 is only marginally stable at body temperature. Hence, 
any mutation that reduces the thermodynamic stability of the protein will have a profound 
effect on the amount of folded protein in the cell [reviewed in (Bullock and Fersht, 2001)]. 
DNA-contact mutants, such as R273H, have only a small effect on the thermodynamic 
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stability of the protein. Instead, structural “hotspot” mutations in the DNA-binding surface 
lead to thermodynamic instability, being functional at low temperature but denature at higher 
temperatures [reviewed in (Butler and Loh, 2005; Friedler et al., 2003)]. Several p53 
mutants reduce the melting temperature of p53, leading to its fast degradation. Indeed, 
R175H and Y220C are examples of p53 mutants dependent on temperature (Gaiddon et 
al., 2001). Highly destabilized mutants unfold more than 10 times faster than the wt core 
domain, whereas the contact mutants have roughly the same half-life as the wt (Butler and 
Loh, 2005; Friedler et al., 2003).  
 
 
Both R175H and R273H mutations (two of the six hotspot mut p53) present a change from 
arginine to histidine amino acids and R280K has a change from arginine to lysine amino 
acids. In the DNA contact mut R273H and R280K, the substitution has little or no effect on 
p53 folding, but directly affects its binding to DNA, while in the structural mut R175H the 
substitution leads to destabilization and conformational perturbations of the protein that 
interfere with its oligomerization and DNA-binding, resulting in more severe changes in the 
protein structure (Vrba et al., 2008). 
Y220C, the ninth most frequent mutation found in human cancers (Figure 9), shows a 
substitution of the tyrosine by cysteine, which leads to a decrease of the thermodynamic 
stability of p53 [reviewed in (Girardini et al., 2014)]. Thus, a druggable cavity is created on 
Figure 10. Functional impact of TP53 mutations. The phenotypic effects of p53 mutation can usually 
confer three non-mutually exclusive characteristics: a dominant negative (DN) effect of mut p53 over the 
wt protein, a loss of function (LOF) and a gain of function (GOF). The GOF plays a role in both contact 
(such as R273H and R280K) and structural mutants (such as R175H and Y220C) [adapted from (Brosh 
and Rotter, 2009)] 
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the surface of the protein at the site of mutation that is particularly suited for pharmacological 
manipulation (Boeckler et al., 2008). 
Finally, mutations at the residues R280K, Y220C, R273H and R175H have been associated 
with GOF activities (Figure 10) (Fontemaggi et al., 2009; Kang et al., 2013; Lang et al., 
2004; Olive et al., 2004). 
 
1.5.1 Reactivation of wild-type function to mutant p53 
Due to the high frequency of p53 mutations in cancer and to the increased resistance of 
mutant p53-expressing tumours to conventional chemo- and radiotherapy, the restoration 
of wt conformation and activity is a promising strategy for cancer therapy. However, based 
on the conventional drug development process, p53 is not an ideal therapeutic target, since 
it is neither an enzyme nor a receptor. Despite the difficulties associated with the 
development of drugs targeting p53, recent technological advances, in association with the 
knowledge about p53 obtained over the past 30 years, made the development of tumour-
specific p53 restoration therapies a realistic ambition [reviewed in (Brosh and Rotter, 2009; 
Chen et al., 2010; Farnebo et al., 2010)]. 
Several strategies have been designed to restore the impaired function of wt p53 in its mut 
forms, including the introduction of second-site mutations, antibody binding, short peptides 
and small molecules [reviewed in (Selivanova and Wiman, 2007)]. The rescue strategies 
vary depending on the mutation types. So, in tumours harbouring a DNA-contact mut, the 
attempts were to introduce functional groups that create new contacts or stabilize the 
scaffolding position in the remaining contact sites. On the other hand, the functions of 
conformation mutants can be restored by a synthetic peptide [reviewed in (Bassett et al., 
2008; Wang and Sun, 2010)] derived from the p53 C-terminal region that, when introduced 
into tumour cells harbouring mut p53, leads to the induction of p53-regulated genes and 
apoptosis, which results in the stabilization of the wt conformation of the mut protein 
(Selivanova et al., 1997). 
More recently, attempts have been made to identify small molecules that reactivate mut 
p53. These molecules should directly interact with mut p53 DBD leading to the restoration 
of wt folding and, consequently, of DNA-binding and transactivation activity to mut p53. This 
strategy led to the identification of small molecules that restore the wt p53 function to several 
p53 mutants. Screening studies have identified small molecules, including CP-31398 
(Foster et al., 1999), ellipticine (Shi et al., 1998), PRIMA-1 (Bykov et al., 2002), MIRA-1 
(Bykov et al., 2005) and RITA (Grinkevich et al., 2009) as reactivating agents of mut p53. 
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The first reported small molecule, CP-31398, allows mut p53-expressing cells to restore the 
protein folding of mutated p53 to a more natural conformation that allows a wt function and 
even impair tumour growth (Table 1) (Foster et al., 1999). Despite this promising start, it 
was later discovered that CP-31398 does not bind to the p53 core domain and does not 
stabilize p53 in vitro, but instead it is a DNA intercalator (Rippin et al., 2002). 
Of the small molecules that target mut p53, the most well studied so far has been PRIMA-
1 (p53-Reactivation and Induction of Massive Apoptosis), which has been shown to 
reactivate missense mut p53. This compound aims to restore sequence-specific DNA 
binding and change the mut p53 conformation to wt, leading to the transactivation of p53 
target genes and thus halt tumour growth. PRIMA-1 rescued both DNA contact and 
structural p53 mutants (Table 1) (Bykov et al., 2002; Lambert et al., 2009). A more potent 
methylated structural analog of PRIMA-1, APR-246/PRIMA-1Met, has advanced to the 
clinical trials, and the phase-I evaluation has been recently completed (Table1) [reviewed 
in (Hoe et al., 2014)]. In contrast to CP-31398, PRIMA-1 does not activate wt p53 (Lambert 
et al., 2009). 
While the above-mentioned compounds target multiple p53 mutants, one of the most 
impressive approaches from recent years has been the development of a structure-based 
‘‘mutant-specific’’ drug, PhiKan083. PhiKan083 is a carbazole derivative found from in silico 
screening of the crystal structure of p53. PhiKan083 binds to a unique pocket in the core 
domain of p53-Y220C, stabilizing the conformation of the core domain and restoring the 
transactivation of p53 target genes. By binding mutated p53, PhiKan083 can raise the 
melting temperature of the mut p53-Y220C, and the rate of thermal denaturation 
subsequently slows down, resulting in the reactivation of p53 function (Table 1) (Boeckler 
et al., 2008; Rauf et al., 2013). A new compound recently developed, PK7088, has also 
shown to bind to Y220C core domain reactivating cellular p53 functions (Liu et al., 2013). 
The small molecule NSC319726 has shown to favour a wt conformation, inducing the 
transcription of wt p53 target genes and apoptosis in cell lines harbouring a R175H 
mutation. Moreover, this compound selectively inhibited xenograft tumour growth of R175H-
mut p53 cells (Yu et al., 2012) (Table 1). 
Another small molecule, SCH529074, was identified in an in vitro DNA-binding assay. This 
compound binds to the DBD of mut p53 working as a chaperone, restoring proper folding 
and DNA-binding activity to mut p53. SCH529074 restores the activity to both DNA contact 
(R273H) and structural (R249S) p53 mutants (Demma et al., 2010) (Table 1). 
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Table 1. Small molecule reactivators of mut p53 through restoration of wt p53 conformation. 
Compound 
Mutant p53 
In vivo anti-
tumour 
activity 
Genotoxicity 
Pre-clinical 
Toxicity 
Clinical 
trials 
Ref 
CP-31398 
R175H 
R280K 
R273H 
Yes Yes Yes 
Data not 
available 
(Foster et al., 1999; 
Rippin et al., 2002) 
Prima-1 
R175H  
R273H 
R280K 
Yes No No 
Data not 
available 
(Bykov et al., 2002; 
Lambert et al., 2009) 
PRIMA-1Met 
(APR-246) 
R175H  
R273H 
Yes No No 
Phase 
I/II 
(Bykov and Wiman, 
2014; Lambert et al., 
2009) 
NSC319726 R175H Yes 
Data not 
available 
No 
Data not 
available 
(Yu et al., 2012) 
Phikan 083 Y220C 
Data Not 
available 
Data not 
available 
Data not 
available 
Data not 
available 
(Boeckler et al., 2008) 
SCH529074 
R273H 
R249S 
Yes 
Data not 
Available 
Data not 
available 
Data not 
available 
(Demma et al., 2010) 
 
 
1.6 Yeast model in the study of p53 related proteins 
The high degree of conservation of cellular processes and molecular pathways with human 
cells has made the yeast Saccharomyces cerevisiae a powerful model to study human 
proteins and the molecular mechanisms underlying the pathobiology of several human 
diseases. Among all eukaryotic organisms, the yeast cell model presents many advantages 
including easy and low-cost manipulation, short generation time and compliance to genetic 
manipulation [reviewed in (Mager and Winderickx, 2005; Pereira et al., 2012a)]. 
S. cerevisiae has greatly contributed to the elucidation of basic cellular processes related 
to cell cycle and cell death, among others [reviewed in (Khurana and Lindquist, 2010)]. 
However, it must be noted that as a unicellular organism some genes involved in human 
disease may not be present in the yeast genome and several aspects of human disorders, 
which rely on multicellularity and cell-cell interactions, are difficult to evaluate. Interestingly, 
if the gene implicated in the human disease is conserved in yeast, its function can be directly 
studied. Moreover the heterologous expression of human proteins in yeast (commonly 
referred to as “humanized yeast”) has brought us the possibility for an independent analysis 
of a wide range of human proteins. However, if the gene implicated in the human disease 
has no orthologues in yeast, its heterologous expression will allow the study of the human 
protein in a simpler eukaryotic environment, without the interference of other proteins with 
similar functions, endogenous regulators and redundant processes, which can be very 
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advantageous [reviewed in (Pereira et al., 2012a; Pereira et al., 2012b)]. This is the case of 
p53 and its negative regulators MDM2 and MDMX, for which no orthologues has been 
identified in yeast, making possible the study of the activity of individual human p53 proteins 
heterologously expressed in this microorganism [reviewed in (Pereira et al., 2012a; 
Smardová et al., 2005)]. 
In fact, over the recent years, several yeast-cell based assays have been developed for 
functional, molecular and pharmacological studies of p53 family proteins. 
The yeast two-hybrid (Y2H) assay is the most known and used assay to study interactions 
between proteins. In this assay, the protein of interest is fused to the DBD of a transcription 
factor, such as Gal4, while the potential interactor protein is fused to a transactivation 
domain (Figure 10B). Upon co-expression, protein-protein interaction is detected because 
association of the two domains of transcription factor leads to the expression of a reporter 
gene (Ratushny and Golemis, 2008). There are many studies that explore the interaction of 
p53 family proteins with other proteins using the Y2H assay. For example, Freedman and 
colleagues performed a modified Y2H assay, in order to determine the amino acids of 
MDM2 that are critical for binding to p53. This method was important to reveal not only that 
the interaction between the anti-apoptotic protein translationally control MDM2 protein and 
p53, but also to find the critical binding sites between these two proteins (Freedman et al., 
1997). Later, Sharp and colleagues, using an Y2H screening protocol to identify other 
factors with a potential role in influencing the expression and/or function of MDM2, reported 
the physical interaction of MDM2 with MDMX (Sharp et al., 1999). The Y2H assay was also 
used to study interactions between members of the p53 family (Kaghad et al., 1997) and 
mutants (Ratovitski et al., 2001). In 1996, Vidal and colleagues developed a reverse Y2H 
assay applicable for drug screening, in which cells grow when the interaction between 
proteins does not occur due to drugs. The reverse Y2H assay is an excellent assay to find 
compounds that inhibit unwanted protein interactions, like inhibitors of p53-MDM2 
interaction (Vidal et al., 1996). 
Ishioka and colleagues described one of the first yeast cell-based assays to study the p53 
family of proteins, the Functional Analysis of Separated Alleles in Yeast (FASAY) assay. 
This technique consists in the amplification of the p53 cDNA, obtained from tumour samples 
or other tissues, by reverse transcriptase PCR (RT-PCR) and in the co-transformation of a 
yeast reporter strain with the PCR product and a gapped expression plasmid. The p53 
status is evaluated using plates without histidine. Yeast clones expressing a functional p53 
are His+ due to the capacity to express the HIS3 reporter gene and will therefore grow; 
yeast clones expressing a mutated p53 are His- and will not grow. In this way, the FASAY 
assay, consists of a functional analysis of the separated alleles of TP53 in yeast in order to 
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evaluate the p53 activity in cancer (Ishioka et al., 1993). Using an improved version of this 
cell system, it was verified that some TP53 mutations led to the partial loss of the p53 
transactivation function (Kovvali et al., 2001). 
More recently it was developed the dual-luciferase functional assay (Figure 11A), which 
uses a luciferase reporter gene containing a p53 response element (RE) placed upstream 
of a minimal promoter (pCYC1). In this way, when wt p53 is activated, it will bind to the p53 
RE, inducing the transcription of the luciferase reporter gene and the synthesis of luciferase. 
Therefore, the p53 transcriptional activity is evaluated by the quantification of the light 
emitted, which is directly proportional to the luciferase oxidative activity. This dual-luciferase 
transactivation assay was adapted to the high throughput screening (HTS) of co-factors and 
small molecules that can influence the p53 network (Andreotti et al., 2011). In spite of all 
the advantages of this yeast-based assay, it is an artificial system, since it relies on the 
insertion of a human reporter gene containing a p53 RE in yeast cells, and an expensive 
cell system for HTS. 
During the last years, our research group has been focused on the development and 
validation of yeast target-based screening assays, for pharmacological research directed to 
distinct cancer-related human proteins, such as protein kinase C (PKC), caspases and p53 
family proteins [reviewed in (Gomez-Casati et al., 2012; Pereira et al., 2012a; Pereira et al., 
2012b)]. 
In our first work with p53, it was confirmed that expression of wt p53 in yeast induced a 
marked growth inhibition associated with S-phase cell cycle (Coutinho et al., 2009). This 
toxic effect of p53 in yeast allowed the development of a yeast phenotypic assay, based on 
simple measurements of cell growth. Additionally, this yeast growth-inhibitory assay was 
used as a screening tool to search for modulators of p53 activity. In subsequent studies, it 
was shown the conservation in yeast of the inhibitory effect of MDM2 and MDMX on p53 
activity. In fact, as in mammalian cells, when co-expressed wt p53 with both MDM2 and 
MDMX markedly reduce the p53 activity in yeast leading to the reduction of the p53-induced 
yeast growth inhibition and cell cycle arrest  (Leão et al., 2013a; Leão et al., 2013b). It was 
also found that the p53-induced yeast growth inhibition and cell cycle arrest, are associated 
with a marked increase of actin protein levels, when compared with the control yeast (Figure 
10C). Moreover, it was shown that the wt p53-induced actin protein levels are modulated 
by natural (MDM2 and MDMX) and chemical (nutlin-3a and SJ-172550) regulators of p53 
activity. Furthermore, wt p53 could stimulate transcription from a minimal promoter 
containing a fragment of the ACT1 upstream sequence. Thus, ACT1 is proposed as a 
putative endogenous p53 target gene (Figure 10C) (Leão et al., 2013b). 
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Using this yeast phenotypic assay, we were able to search for new inhibitors of the p53-
MDM2 and p53-MDMX interactions. In fact, the use of this cell system led to the 
identification of new small molecules inhibitors of the p53-MDM2 interaction such as the 
compound with a xanthone scaffold (LEM1) (Leão et al., 2013a), two other xanthone 
derivatives, the α-mangostin and gambogic acid (Leao et al., 2013) and, more recently, a 
compounds with an oxazoloisoindolinone scaffold (Soares et al., 2014b).  
Despite some limitations, the yeast screening assay as proved to be effective in a first-line 
screening of potential active compounds, reducing the costs and expediting the discovery 
of new drugs. 
Figure 11. Schematic representation of three yeast models to study p53. A) Yeast-based p53 dual-
luciferase transactivation assay expressing human wt/mut p53 or co-expressing human wt p53 and a 
co-factor (for example MDM2). The p53 transcriptional activity is evaluated by quantification of the 
luciferase activity, which is directly proportional to the light units measured in a plate reader. B) Yeast 
two-hybrid assay, in which the coding sequence of protein X (bait) is fused to the GAL4-DBD and the 
coding sequence of protein Y (Prey) is fused to the GAL4-AD. With the interaction of the two proteins X 
and Y, the functionality of the transcription factor is reconstituted, GAL4 binds to its specific Upstream 
Activation Sequence leading to the transcription of the reporter gene. C) Yeast p53-MDM2/p53-MDMX 
phenotypic assay. The expression of wt p53 induces growth inhibition and increases the actin protein 
levels, which is reverted by MDM2 and MDMX. 
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1.7  Aims of research  
The main objectives of this thesis were to: 
i)  Use a previously developed yeast target-directed screening approach to search for 
new small molecule inhibitors of the p53-MDM2/MDMX interaction; 
ii) Validate in human tumour cell lines the molecular mechanism of action of potential 
dual inhibitors of the p53-MDM2/MDMX interaction identified in yeast; 
iii) Develop a new yeast target-directed screening assay to search for reactivators of 
some of the most prevalent human mut p53 forms, namely R280K, R175H, R273H and 
Y220C. 
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Chapter 2 
. OXAZ-1: a new small molecule 
with in vitro antitumour activity 
through selective activation of 
a mitochondria-mediated p53 
pathway and potential 
MDM2/MDMX inhibition 
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2 Introduction 
MDM2 and MDMX are two major factors that contribute to cancer development due to the 
inactivation of wt p53. Disruption of the p53-MDMs regulatory network has therefore clear 
implications for tumorigenesis and presents exciting opportunities for cancer therapy (Wade 
et al., 2013). The antitumour activity of small molecule inhibitors of the p53-MDMs 
interaction has already been confirmed in preclinical studies and early-phase of clinical 
trials. However, to date, most of the current efforts have been focused on the p53-MDM2 
interaction (Li and Lozano, 2013; Wade et al., 2013). The role of MDMX in the fine regulation 
of p53 is still emerging, but it is well-established that even normal levels of MDMX can 
partially silence activated p53. Additionally, MDMX overexpression (namely in 
retinoblastomas and melanomas) renders cancer cells highly resistant to MDM2-only 
inhibitors, such as nutlin-3a, since they are unable to liberate p53 from MDMX (Graves et 
al., 2012; Li and Lozano, 2013). This clearly indicates that dual inhibition of MDM2 and 
MDMX may substantially improve the outcome of this p53 activation strategy due to the full 
p53 activation (Li and Lozano, 2013; Wade et al., 2013). In spite of this, recent efforts to 
develop this type of molecules have been hindered by structural differences in the p53 
pockets of MDM2 and MDMX (Riedinger and McDonnell, 2009). In fact, only recently, the 
small molecules based on a pyrrolopyrimidine scaffold (Lee et al., 2011) and RO-5963 
(Graves et al., 2012) were identified as dual inhibitors of MDM2 and MDMX.  
In this chapter, we report the identification of a potential dual inhibitor of the p53 interaction 
with MDM2 and MDMX, the N-tosylindole OXAZ-1, from the screening of a small library of 
tryptophanol-derived oxazolopiperidone lactams, using a yeast assay. The identification of 
this selective activator of the p53 pathway may open the way to the development of a new 
class of dual MDM2/MDMX inhibitors with promising applications in anticancer therapy.  
 
2.1 Material and methods 
2.1.1 Compounds 
OXAZ-2, OXAZ-3, OXAZ-4, OXAZ-5, and OXAZ-6, whose molecular structures are shown 
in Figure 11 were synthesized according to the described procedures (Amat et al., 2007a; 
Amat et al., 2007b; Pereira et al., 2014). 
Nutlin-3a was from Alexis Biochemicals (Grupo Taper, Sintra, Portugal); doxorubicin and 
SJ-172550 were from Sigma-Aldrich (Sintra, Portugal); etoposide was from Calbiochem 
(VWR, Carnaxide, Portugal). All tested compounds were dissolved in dimethyl sulfoxide 
(DMSO) from Sigma-Aldrich (Sintra, Portugal). 
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2.1.2 Synthesis of OXAZ-1 
A solution of tryptophanol-derived oxazolopiperidone lactam OXAZ-5 (1 eq.) in CH2Cl2 was 
cooled to 0°C. p-Toluenesulphonyl chloride (1.2 eq.) and tetrabutylammonium chloride (cat., 
10% mmol) were added and the mixture was stirred for 10 min. Then, an aqueous solution 
of NaOH (30% m/v, 0.5 v CH2Cl2) was added and the reaction was allowed to stand at room 
temperature for 24 h. After this period, the reaction was diluted with CH2Cl2 and the phases 
were separated. The organic phase was washed with HCl (1M) and dried over Na2SO4. 
After solvent evaporation the crude compound was purified by flash chromatography 
(EtOAc/n-hexane 1:1). The desired compound was recrystallized from dichoromethane. 1H 
NMR (400 MHz, CDCl3) δ 7.96 (d, J = 8.1 Hz, 1H), 7.72 (m, 3H), 7.36 (s, 1H), 7.31 (t, J = 
7.7 Hz, 1H), 7.25 (m, 1H), 7.21 (m, 2H), 4.70 (dd, J = 9.9, 2.5 Hz, 1H), 4.23 (m, 1H), 3.95 
(d, J = 9.4 Hz, 1H), 3.74 (t, J = 7.8 Hz, 1H), 3.70 (s, 3H), 3.58 (d, J = 14.1 Hz, 1H), 2.68 (dd, 
J = 14.0, 9.8 Hz, 1H), 2.60 (dd, J = 17.6, 4.6 Hz, 1H), 2.37 (m, 3H), 2.33 (s, 3H), 2.28 (d, J 
= 12.0 Hz, 1H), 2.10 (dd, J = 17.6, 10.2 Hz, 1H), 1.21 (m, 1H). Elemental Anal. calcd. for 
C26H28N2O6S: C 62.89, H 5.68, N 5.64, found: C 62.98, H 5.84, N 6.00. The 1H NMR spectra 
was found to be identical to the one described in (Amat et al., 2007b). 
 
2.1.3 Plasmids 
The yeast expression vectors were used: pGADT7-(LEU2) encoding human MDM2 (kindly 
provided by Dr Xue-Min Zhang; National Center of Biomedical Analysis, China) or MDMX 
(kindly provided by Dr Martin Scheffner; University of Konstanz, Germany) under ADH1 
constitutive promoter; pLS89-(TRP1) encoding human wt p53 under GAL1-10 inducible 
promoter (kindly provided by Dr Richard Iggo; Swiss Institute for Experimental Cancer 
Research, Switzerland).  
 
2.1.4 Yeast target-directed screening assay 
S. cerevisiae (strain CG379) expressing human wt p53 alone and combined with human 
MDM2 or MDMX were obtained in previous works (Leão et al., 2013a; Leão et al., 2013b). 
For expression of human proteins, cells (routinely grown in minimal selective medium) were 
diluted to 0.05 OD600 in selective induction medium containing 2% (w/w) galactose, 1% 
(w/w) raffinose, 0.7% (w/w) yeast nitrogen base without amino acids from Difco (Quilaban, 
Sintra, Portugal) and all the amino acids required for yeast growth (50 mg/mL) except 
leucine and tryptophan. Yeast cells were incubated at 30 ºC under continuous orbital 
shaking (200 r.p.m.) with 0.1 – 50 μM compounds or 0.1% DMSO only, for approximately 
42 h (time required by control yeast, co-transformed with the empty vectors pLS89 and 
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pGADT7 incubated with DMSO only to achieve 0.4 OD600). Yeast growth was analysed by 
counting the number of colony-forming units (CFU) after 2 days incubation at 30 ºC on 
Sabouraud Dextrose Agar from Liofilchem (Frilabo, Porto, Portugal). 
 
2.1.5 Human tumour cell lines and growth conditions 
The human colon adenocarcinoma HCT116 cell line harbouring a wt p53 form (HCT116 
p53+/+), and its isogenic derivative in which p53 has been knocked out (HCT116 p53-/-), and 
the human breast adenocarcinoma MCF-7 tumour cell line were used. Cell lines were 
routinely cultured in RPMI-1640 with ultraglutamine medium from Lonza (VWR, Carnaxide, 
Portugal) supplemented with 10% fetal bovine serum from Gibco (Alfagene, Carcavelos, 
Portugal) and maintained in a humidified incubator at 37 °C with 5% CO2 in air.  
 
2.1.6 Sulforhodamine B (SRB) assay 
For the analyses of the effect of compounds on the in vitro growth of human tumour cell 
lines, cells were plated in 96-well plates at a final density of 5.0 × 103 cells/well and 
incubated for 24 h. Cells were then exposed to serial dilutions of compound (from 1.85 to 
150 μM). The effect of the compounds was analysed following 48 h incubation, using the 
SRB assay. Briefly, following fixation with 10% trichloroacetic acid, plates were stained with 
0.4% SRB, both from Sigma-Aldrich (Sintra, Portugal), and washed with 1% acetic acid. 
The bound dye was then solubilized with 10 mM Tris Base and the absorbance was 
measured at 510 nm in a microplate reader (Biotek Instruments Inc., Synergy MX, USA). 
The solvent of the compounds (DMSO) corresponding to the maximum concentration used 
in these assays (0.25%) was included as control. The concentration of the compound that 
causes a 50% reduction in the net protein increase in cells during treatment (GI50, growth 
inhibition of 50%) was determined for all tested compounds. 
 
2.1.7 Analysis of cell cycle and apoptosis in human tumour cell lines 
HCT116 p53+/+ and MCF-7 cells were plated in 6-well plates at a final density of 1.5 × 105 
cells/well. After 24 h incubation, cells were treated with the GI50 and with twice the GI50 
concentration (2xGI50) of OXAZ-1 or DMSO only for 24 h. For cell cycle analysis, cells were 
thereafter fixed in ice-cold 70% ethanol and incubated at 37 ºC with RNase A from Sigma-
Aldrich (Sintra, Portugal) at a final concentration of 20 μg/mL for 15 min, and further 
incubated with 50 µg/mL propidium iodide (PI) from Fluka (Sigma-Aldrich, Sintra, Portugal) 
for 30 min, followed by flow cytometric analysis. For apoptosis analysis, cells were analysed 
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by flow cytometry using the Annexin V-FITC Apoptosis Detection Kit I from BD Biosciences 
(Enzifarma, Porto, Portugal), according to the manufacturer’s instructions. 
 
2.1.8 Western blot analysis 
To prepare whole protein extracts from yeast, these cells were lysed with CellyticTM Y Cell 
Lysis Reagent containing EDTA-free protease inhibitor cocktail from Sigma-Aldrich (Sintra, 
Portugal). To prepare the whole protein extracts from human tumour cell lines, cells were 
lysed with RIPA buffer containing EDTA-free protease inhibitor cocktail from Sigma-Aldrich 
(Sintra, Portugal). For mitochondrial and cytosolic fractions of human tumour cell lines, the 
Mitochondrial Fractionation Kit from Active Motif (Frilabo, Porto, Portugal) was used 
according to the manufacturer’s instructions.  
Whole protein extracts were quantified using the Coomassie staining Bradford from Sigma-
Aldrich (Sintra, Portugal). Proteins (40 µg) were electrophoresed using a 10% SDS-PAGE 
and transferred to a Whatman nitrocellulose membrane from Protan (VWR, Carnaxide, 
Portugal). Membranes were blocked with 5% milk and probed with a mouse monoclonal 
anti-p53 (DO-1), anti-MDM2 (D-12), anti-Bax (2D2), anti-PUMA (B-6), anti-PARP (C2-10) 
and anti-cytochrome c (A-8) followed by an anti-mouse horseradish-peroxidase (HRP)-
conjugated secondary antibody. For p21, MDMX and actin detection, membranes were 
probed with a rabbit polyclonal anti-p21 (C-19), anti-MDMX (A300), and anti-actin (C11), 
respectively, followed by an anti-rabbit horseradish-peroxidase (HRP)-conjugated 
secondary antibody. For loading control, membranes were stripped and reprobed with a 
mouse monoclonal anti-yeast phosphoglycerate kinase (Pgk1p) or anti-GAPDH (6C5). For 
analyses of mitochondrial and cytosolic fractions, membranes were reprobed with the 
loading controls mouse monoclonal anti-GAPDH (6C5) or anti-Cox4 (F-8), used to exclude 
putative contamination of cytosolic and mitochondrial fractions, respectively. All antibodies 
were purchased from Santa Cruz Biotechnology (Frilabo, Porto, Portugal), except the anti-
MDMX from Bethyl Laboratories (bioNova cientifica, Madrid, Spain) and the anti-Pgk1p from 
Alfagene (Molecular probes, Carcavelos, Portugal). The signal was detected with the ECL 
Amersham kit from GE Healthcare (VWR, Carnaxide, Portugal) and with the Kodak GBX 
developer and fixer from Sigma-Aldrich (Sintra, Portugal). Band intensities were quantified 
using the Bio-Profil Bio-1D++ software (Vilber-Lourmat, Marne La Vallée, France). 
 
 
ICBAS 
Drugging p53 in cancer 41 
 
2.1.9 Co-immunoprecipitation assay 
To perform the co-immunoprecipitation (co-IP), the Pierce Classic Magnetic IP and Co-IP 
Kit from Thermo scientific (Dagma, Carcavelos, Portugal) was used according to the 
manufacturer’s instructions. Briefly, cells were plated at a final density of 5 × 105 cells/plate 
and incubated for 24 h. Cells were then treated with 25, 50 and 75 µM of OXAZ-1 or DMSO 
only for 16 h. After cell lysis and protein lysate separation, 500 µg of total protein was 
incubated with 2 µL of mouse monoclonal anti-p53 (DO-1) or with mouse immunoglobulin 
G (IgG, control) from Santa Cruz Biotechnology (Frilabo, Porto, Portugal), overnight at 4 °C. 
Immunocomplexes were immunoprecipitated using magnetic beads. Detection of p53, 
MDM2, MDMX, and GAPDH (loading control) in whole cell lysate (input) and in 
immunoprecipitated fraction was performed by Western blot analysis as in section 2.1.8  
 
2.1.10 Analysis of mitochondrial transmembrane potential (∆ψm) 
For analysis of ∆ψm, HCT116 p53+/+   tumour cells were plated in 6-well plates at a final 
density of 1.5 × 105 cells/well. After 24 h incubation, cells were treated with the GI50 
concentration of OXAZ-1 or DMSO only for 8 h. Cells were harvested and incubated with 1 
nM 3,3'-Dihexyloxacarbocyanine Iodide [DiOC6(3); Alfagene (Molecular probes, 
Carcavelos, Portugal)] for 30 min at 37 °C; cells treated with 50 μM carbonilcyanide p-
triflouromethoxyphenylhydrazone (FCCP; Sigma-Aldrich, Sintra, Portugal), for 15 min at 37 
ºC, were used as positive control of dissipation of ∆ψm potential. 
 
2.1.11 Analysis of reactive oxygen species (ROS) production 
Analysis of intracellular ROS generation was performed by flow cytometry. Briefly, HCT116 
p53+/+ tumour cells were plated in 6-well plates at a final density of 1.5 × 105 cells/well and 
incubated for 24 h. Cells were then treated with the GI50 concentration of OXAZ-1 or DMSO 
only for 48 h. Cells were harvested and stained with 5 μM CellROX Green Reagent from 
Life Technologies (Alfagene, Carcavelos, Portugal) for 30 min at 37 ºC.  
 
2.1.12 Flow cytometric data acquisition and analysis 
For the flow cytometric analysis, the AccuriTM C6 flow cytometer from BD Biosciences 
(Enzifarma, Porto, Portugal) and the CellQuest software from BD Biosciences (Enzifarma, 
Porto, Portugal) were used. For the identification and quantification of cell cycle phases the 
ModFit LT software (Verity Software House Inc., Topsham, USA) was used. 
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2.1.13 Computational chemistry  
The OXAZ-1 chemical structure was built with MOE and energetically minimized using the 
MMFF94x force field with a RMS gradient of 0.1. The crystallographic structure of MDM2 
protein bound to the MI-63 analog (PDB code: 3LBL) was imported in MOE and the co-
crystallized waters were removed. Only the C chain was kept and the residues were 
protonated to match their state at physiological pH using the protonate 3D module of MOE. 
The binding pocket was defined by using alpha spheres (sphere that contacts 4 atoms on 
its boundary and contains no internal atoms) within 5 Å of the MI-63 analog crystallographic 
pose. For MDMX, a similar procedure was used with the 3LBJ crystallographic structure by 
removing extra co-crystallized molecules but retaining the WK298 inhibitor located in the 
p53 experimental docking cleft. 
All docking experiments were performed using a triangle matcher placement with a London 
dG scoring and a MMFF94x force field refinement followed by a GBVI/WSA dG re-scoring 
(defaults in MOE 2013.08). This protocol was tested by re-docking the co-crystallized 
inhibitors (MI-63 analog in MDM2 and WK298 in MDMX). The top ranked poses were very 
similar to the experimental ones and correctly reproduced the main interaction features (as 
expected, the largest variation was on the terminal carbon chain of WK298). 
The results were ranked through their binding affinities and the molecular interactions were 
interpreted based on the best scored conformation per structure. 
 
2.1.14 Statistical analysis 
Data were analysed statistically using the GraphPad software. Differences between means 
were tested for significance using the Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001). 
 
2.2 Results 
2.2.1 Identification of OXAZ-1 as potential dual inhibitor of the p53 interaction 
with MDM2 and MDMX in yeast 
In this work, six oxazolopiperidinone lactams (Figure 12) were evaluated as dual inhibitors 
of the p53 interaction with MDM2 and MDMX using yeast target-directed screening assays. 
These compounds contain, in the same structure, two privileged scaffolds in MDM2 
inhibitors design: the piperidinone and indole skeletons (Sun et al., 2014).  
Compounds OXAZ-2, OXAZ-3, OXAZ-4, and OXAZ-5 were synthesised by 
cyclocondensation reaction of (S)-tryptophanol and the appropriate δ-oxo-esters (Amat et 
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al., 2007a; Amat et al., 2007b; Pereira et al., 2014). The lactams OXAZ-3, and OXAZ-5 
were converted to the N-tosylindole derivatives OXAZ-6 and OXAZ-1, respectively, with 
high yields (Amat et al., 2007b). 
 
 
 
Figure 12. Chemical structure of tryptophanol-derived oxazolopiperidone lactams evaluated in 
yeast. 
 
The effect of the synthesized compounds as inhibitors of the p53-MDM2/X interaction was 
thereafter tested using previously developed yeast target-directed screening assays (Leão 
et al., 2013a; Leão et al., 2013b). These yeast assays are based on the fact that human 
p53 is also a transcription factor in yeast inducing a marked growth inhibition, which is 
abolished by human MDM2 and MDMX (Figure 13A). As in mammalian cells, inhibitors of 
the p53-MDMs interaction reduce the impact of MDMs on p53 activity, thus restoring the 
p53-induced yeast growth inhibition (Figure 13A). The efficiency of these yeast assays to 
search for inhibitors of the p53 interaction with MDM2 and MDMX was validated by testing 
nutlin-3a (a known inhibitor of the p53-MDM2 interaction) (Vassilev et al., 2004) and SJ-
172550 (a known inhibitor of the p53-MDMX interaction) (Reed et al., 2010), respectively. 
As in mammalian cells (Graves et al., 2012), also in yeast nutlin-3a did not interfere with the 
MDMX inhibitory activity, confirming its activity as MDM2-only inhibitor (Table 2; Figure 
13B). On the other hand, SJ-172550 did not interfere with the MDM2 inhibitory activity, only 
reverting the MDMX inhibitory effect (Table 2; Figure 13B). 
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Table 2. EC50 values obtained for the compounds tested in yeast. 
 
Compounds 
EC50 (µM) 
p53-MDM2 p53-MDMX 
Nutlin-3a 1.6 ± 3.6 > 50 
SJ-172550 > 50 12.4 ± 4.3 
OXAZ-1 1.0 ± 2.4 2.4 ± 3.7 
OXAZ-2 2.3 ± 3.7 > 50 
OXAZ-3 2.0 ± 3.3 > 50 
OXAZ-4 2.1 ± 2.4 > 50 
OXAZ-5 > 50 > 50 
OXAZ-6 3.0 ± 3.3 > 50 
 
Yeast cells co-expressing p53 with MDM2 or MDMX were incubated with 0.1 - 50 µM compounds or 
DMSO only, for 42 h. The EC50 (concentration that caused 50% of the reversion effect) values were 
determined from concentration-response curves of the reversion of the MDM2 or MDMX inhibitory effects 
obtained for 0.1 - 50 µM compound (see Figure 12B for OXAZ-1 and positive controls). Data are mean ± 
S.E.M. of 6 independent experiments. 
 
Using this yeast approach, the effect of 0.1 - 50 µM compounds was evaluated. From the 
concentration-response curves of the reversion of the MDM2 and MDMX inhibitory effects 
obtained for each compound, it was shown that, with the exception of OXAZ-5, all the other 
tested compounds presented similar effects to nutlin-3a, reverting the MDM2 inhibitory 
effect, and therefore behaved as potential inhibitors of the p53-MDM2 interaction (Table 2). 
In spite of this, only OXAZ-1 reverted the MDMX inhibitory effect, exhibiting a higher potency 
than SJ-172550 (Table 2). In fact, contrary to nutlin-3a and SJ-172550, OXAZ-1 reverted 
the inhibitory effects of both MDMs (Table 2; Figure 13B). Additionally, OXAZ-1 did not 
interfere with the growth of control yeast and yeast expressing p53, MDM2 or MDMX alone 
(Figure 13C). 
In a recent work, it was shown that expression of human p53 in yeast also increased the 
expression levels of ACT1 (described as a yeast p53 target gene) (Leão et al., 2013b), an 
effect abolished by MDM2 and MDMX, and re-established by nutlin-3a and SJ-172550, 
respectively (Leão et al., 2013b). Here, it was shown that, similarly to nutlin-3a (for MDM2) 
and SJ-172550 (for MDMX),  the treatment of yeast cells co-expressing p53 with MDM2 or 
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MDMX with OXAZ-1 (at 10 µM for MDM2 and 20 µM for MDMX) increased the actin protein 
levels, when compared to yeast treated with DMSO only (Figure 13D). 
 
Figure 13. Identification of OXAZ-1 as potential dual inhibitor of the p53 interaction with MDM2 and 
MDMX, using a yeast screening assay. (A) Schematic representation of the yeast target-directed 
screening assay. Human MDM2 and MDMX block the growth inhibition and the increase of actin 
expression levels induced by human wt p53 due to the inhibition of p53 transcriptional activity. Nutlin-3a 
and SJ-172550 (positive controls) revert the MDM2 and MDMX inhibitory effects, respectively, on p53, re-
establishing the p53 activity. (B) Effect of 0.1 – 50 µM OXAZ-1, nutlin-3a and SJ-172550 on the reversion 
of p53-induced yeast growth inhibition by MDM2 and MDMX, after 42 h incubation. The growth of yeast 
cells co-expressing p53 and MDM2/MDMX was evaluated by CFU counts; results were plotted setting as 
100% the growth achieved with yeast cells expressing p53 alone incubated with DMSO only; data are 
mean ± S.E.M. of six independent experiments; values significantly different from DMSO only are indicated 
(*p < 0.05, **p < 0.01, ***p < 0.001). (C) Effect of 0.1 – 50 µM OXAZ-1 on the growth of yeast cells 
expressing p53 alone and control yeast after 42 h incubation. Yeast cell growth was evaluated by CFU 
counts; results were plotted setting as 100% the growth achieved with DMSO only; data are mean ± S.E.M. 
of five independent experiments; values are not significantly different from DMSO only (p > 0.05). (D) 
Effect of 10 µM OXAZ-1 on the actin protein levels of yeast cells co-expressing p53 and MDM2/MDMX 
after 42 h incubation. Immunoblots represent one of two independent experiments; Pgk1p was used as 
loading control. 
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Together, the results obtained in yeast indicated that N-tosylindole OXAZ-1 was a potential 
dual inhibitor of the p53 interaction with MDM2 and MDMX. With the absence of a direct 
effect of OXAZ-1 on wt p53 activity, the results obtained may indicate that as inhibitor of 
p53-MDM2/X interaction, OXAZ-1 may act on MDM2 and MDMX. 
 
2.2.2 OXAZ-1 induces a p53-dependent growth inhibitory effect with 
inhibition of the p53-MDM2/MDMX interaction in human tumour cells 
The tumour cell growth inhibitory potential of OXAZ-1 and the contribution of the p53 
pathway to its activity were thereafter ascertained using the human colon adenocarcinoma 
HCT116 cell lines with wt p53 (HCT116 p53+/+) and its p53-null isogenic derivative (HCT116 
p53-/-). The GI50 values obtained for OXAZ-1, after 48 h treatment, of 25 µM in HCT116 
p53+/+ cells and of 66.3 µM in HCT116 p53-/- cells (Figure 14A) revealed a p53-dependent 
growth inhibitory effect by OXAZ-1. In fact, a significant reduction of the potency of OXAZ-
1 was observed when the p53 pathway was knocked out in HCT116 p53-/- cells. 
In HCT116 p53+/+ cells, the growth inhibitory effect of OXAZ-1, at the GI50 and twice the GI50 
(2xGI50) concentration, was associated to G0/G1-phase cell cycle arrest (Figure 14B) and 
to late apoptosis (Figure 14C). The activation of a p53-dependent apoptotic pathway by 
OXAZ-1 was also supported by the occurrence of an increase of cleaved PARP, a product 
of caspase-3 activation, in p53+/+, but not in p53-/-, HCT116 cells (Figure 14D). 
To further ascertain whether OXAZ-1 had effects on tumour cells consistent with an 
inhibition of the p53 interaction with MDM2 and MDMX, the protein levels of p53 and of p53 
target genes were checked by Western blot analysis in p53+/+ and p53-/- HCT116 cells. The 
obtained results showed an increase of the p53 baseline levels in HCT116 p53+/+ cells upon 
25 µM OXAZ-1 treatment (Figure 15A). Moreover, 25 µM OXAZ-1 increased the protein 
levels of major p53 transcription targets in p53+/+, but not in p53-/-, HCT116 cells, namely of 
MDM2, MDMX (recently recognised as a p53 target gene) (Li et al., 2010; Phillips et al., 
2010), the cell cycle regulator p21, and the apoptotic proteins of the Bcl-2 family, Puma and 
Bax (Figure 15A). Moreover, the ability of OXAZ-1 to block the intracellular interaction of 
p53 with MDM2 and MDMX, in HCT116 p53+/+ cells, was further demonstrated by co-IP 
(Figure 15B). The obtained results confirmed that OXAZ-1 inhibited the interaction of p53 
with both MDM2 and MDMX, particularly at 50 and 75 µM. In fact, at these concentrations 
of OXAZ-1, little or no MDM2 co-immunoprecipitated with p53, and a visible decrease of the 
amount of MDMX co-immunoprecipitated with p53 was observed (Figure 15B).   
Additionally, in tumour cells with a decreased wt p53 activity by MDM2 and MDMX, OXAZ-
1 reduced the MDM2-mediated p53 degradation and the MDM2- and MDMX-inhibitory 
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effect on p53 transcriptional activity, leading to the subsequent up-regulation of p53 target 
genes, which supports a potential inhibition of MDM2 and MDMX by OXAZ-1. 
 
 
Figure 14. OXAZ-1 induces a p53-dependent growth inhibition associated with cell cycle arrest and 
apoptosis in human colon adenocarcinoma HCT116 tumor cells. (A) The GI50 concentration of 
OXAZ-1 was determined in p53+/+ and p53-/- HCT116 cells, after 48 h incubation, using the SRB assay. 
Data are mean ± S.E.M. of four independent experiments; values significantly different from HCT116 
p53+/+ cells are indicated (**p < 0.01). (B) OXAZ-1 induces G0/G1-phase cell cycle arrest in HCT116 
p53+/+ cells. The effect was determined after 24 h treatment with 25 µM (GI50) and 50 µM (2xGI50) of 
OXAZ-1; cell cycle phases were analyzed by flow cytometry using PI and quantified using ModFit LT 
software; data are mean ± S.E.M. of two independent experiments; values significantly different from 
DMSO are indicated ( **p < 0.01, ***p < 0.001). (C) OXAZ-1 induces late apoptosis in HCT116 p53+/+ 
cells. The effect was determined after 24 h treatment with 25 µM (GI50) and 50 µM (2xGI50) of OXAZ-1. 
Apoptosis was analyzed by flow cytometry using FITC-Annexin V and PI; data are mean ± S.E.M. of two 
independent experiments; values significantly different from DMSO are indicated (***p < 0.001). (D) OXAZ-
1 leads to PARP cleavage in p53+/+, but not in p53-/-, HCT116 cells. Western blot analysis was performed 
after 24 h treatments with 25 µM OXAZ-1 or DMSO only; immunoblots represent one of two independent 
experiments; GAPDH was used as loading control 
 
 
 
ICBAS 
Drugging p53 in cancer 48 
 
 
In addition, in HCT116 p53+/+ tumour cells, it was observed that 25 µM OXAZ-1 led to a 
marked increase of ROS production and ∆ψm dissipation (Figure 14A). Moreover, besides 
the increase of Bax production (Figure 16A), 25 µM OXAZ-1 triggered the translocation of 
this mitochondrial protein of the Bcl-2 family from the cytosol to mitochondria (Figure 16B), 
a typical event of the mitochondrial apoptotic pathway. Finally, an increase of the cyt c levels 
was observed in the cytosolic fraction of tumour cells after 24 h treatment with 25 µM OXAZ-
1, indicating its release into the cytosol from mitochondria (Figure 16C). Together, these 
results showed that OXAZ-1 was a potent inducer of a mitochondrial-dependent apoptotic 
cell death in human tumour cells. 
Figure 15. OXAZ-1 leads to p53 stabilization and to the up-regulation of p53 target genes by 
blocking the p53 interaction with MDM2 and MDMX in HCT116 p53+/+ tumor cells. (A) OXAZ-1 
increased the protein levels of p53, MDM2, MDMX, p21, Puma and Bax in p53+/+, but not in p53-/-, 
HCT116 cells. Western blot analysis was performed after 24 h treatment with 25 µM OXAZ-1 or DMSO 
only; immunoblots represent one of two independent experiments; GAPDH was used as loading control. 
(B) HCT116 p53+/+ cells were treated with 25, 50 and 75 µM OXAZ-1 or DMSO only for 16 h, followed by 
IP with p53 or mouse immunoglobulin G (IgG) antibodies, and Western blot with MDM2, MDMX and p53 
antibodies; whole cell lysate (input); GAPDH was used as loading control. 
ICBAS 
Drugging p53 in cancer 49 
 
 
 
 
Figure 16. OXAZ-1 induces a mitochondrial-dependent apoptotic pathway in HCT116 p53+/+ tumour 
cells. (A) HCT116 p53+/+ cells were treated for 8 h (in ∆ψm analysis) or for 48 h (in analysis of ROS 
production) with 25 µM OXAZ-1 or DMSO only. For assessment of ROS production and ∆ψm, cells were 
stained with CellROX and DIOC6(3), respectively, and analysed by flow cytometry; histograms represent 
one of two independent experiments; M2 cursor indicates the subpopulation analysed; values correspond 
to the increase in the percentage of CellROX positive cells (in analysis of ROS production) and of cells 
with ∆ψm dissipation obtained after treatment with OXAZ-1 and are mean ± S.E.M. of two independent 
experiments. In the ∆ψm analysis, FCCP was used as positive control. (B) 25 µM OXAZ-1 induces 
translocation of Bax from cytosol to mitochondria. (C) 25 µM OXAZ-1 triggers mitochondrial cyt c release 
into the cytosol after 24 h treatment. Immunoblots represent one of two independent experiments; GAPDH 
and COX-IV were used as loading controls of cytosolic and mitochondrial fractions, respectively. 
 
 
2.2.3 MDMX-overexpression tumour cells are highly sensitive to OXAZ-1  
Tumour cells overexpressing MDMX have been described as fairly insensitive to MDM2-
only inhibitors (e.g. nutlin-3a), due to its inability to inhibit the p53-MDMX interaction, leading 
to an incomplete restoration of p53 activity (Graves et al., 2012; Patton et al., 2006; Wade 
et al., 2006). Based on this, the effect of OXAZ-1 was tested in human breast cancer MCF-
7 cells, a well-known MDMX-overexpressing tumour cell line (Graves et al., 2012). As 
expected, a similar growth inhibitory effect to that observed in HCT116 p53+/+ cells was 
achieved with OXAZ-1 in MCF-7 cell lines (GI50 value of 23.5 ± 2.5 M). Additionally, as in 
HCT116 p53+/+ cells, also in MCF-7 tumour cells, the OXAZ-1 growth inhibitory effect was 
associated to a G0/G1-phase cell cycle arrest (Figure 17A) and to a late apoptotic cell death 
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(Figure 17B) with PARP cleavage (Figure 17C). Moreover, also in MCF-7 tumour cells, 23.5 
M OXAZ-1 led to the stabilization of p53 protein levels and to the up-regulation of p53 
transcription targets involved in cell cycle (p21) and apoptosis (Bax) (Figure 17D).  
Altogether, these results showed that also in MDMX-overexpression tumour cells OXAZ-1 
was able to activate the p53 pathway predominantly inhibited by MDMX.  
 
 
 
Figure 17. OXAZ-1 exhibits antitumour activity against MDMX-overexpressing human breast 
adenocarcinoma MCF-7 tumour cells through activation of the p53 pathway. (A) OXAZ-1 induces 
G0/G1-phase cell cycle arrest in MCF-7 cells. The effect was determined after 24 h treatment with the 
2xGI50 (47 µM) of OXAZ-1; cell cycle phases were analysed by flow cytometry using PI; data are mean ± 
S.E.M. of two independent experiments; values significantly different from DMSO are indicated (**p < 
0.01). (B) OXAZ-1 induces late apoptosis in MCF-7 cells. The effect was determined after 24 h treatment 
with the 2xGI50 concentration of OXAZ-1. Apoptosis was analysed by flow cytometry using FITC-Annexin 
V and PI; data are mean ± S.E.M. of two independent experiments; values significantly different from 
DMSO are indicated (*p < 0.05). (C, D) OXAZ-1 leads to PARP cleavage (C), and increases the protein 
levels of p53, p21 and Bax (D) in MCF-7 tumour cells. Western blot analysis was performed after 24 h 
treatments with 23.5 µM OXAZ-1 or DMSO only; immunoblots represent one of two independent 
experiments; GAPDH was used as loading control; band intensities were normalized against the control 
sample (DMSO), which was set as 1. 
 
 
2.2.4 OXAZ-1 sensitizes tumour cells to chemotherapeutic drugs 
It was also investigated if OXAZ-1 increased the sensitivity of tumour cells to the effects of 
conventional chemotherapeutic drugs such as doxorubicin and etoposide. For that, we 
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investigated the effect of very low concentrations of OXAZ-1 (approximately the GI5 to GI10 
concentration; for which no significant effects on tumour cell growth were observed), on the 
growth of HCT116 p53+/+ cells in combination with increasing concentrations of doxorubicin 
and etoposide (Figure 18). The results showed that OXAZ-1 significantly increased the 
sensitivity of tumour cells (from 12% to 19%) at the three concentrations tested of 
doxorubicin and etoposide. 
 
 
Figure 18. OXAZ-1 sensitizes tumour cells to the effects of doxorubicin and etoposide. The effect 
of the compounds on cell growth was analysed following 48 h incubation, using the SRB assay. HCT116 
p53+/+ tumour cells were treated with increasing concentrations of doxorubicin (9.38 to 37.5 nM) or 
etoposide (0.38 to 3.00 µM) in the presence of a very low concentration (between GI5 to GI10) of OXAZ-1 
or DMSO only. Data are mean ± S.E.M. of three to four independent experiments. Values significantly 
different from DMSO are indicated (**p < 0.01; ***p < 0.001). 
 
2.2.5 Analysis of the predicted binding model of OXAZ-1 to MDM2 and 
MDMX supports that OXAZ-1 binds to both MDM proteins 
The OXAZ-1 molecule, presenting the highest percentage of reversion effect on both MDM2 
and MDMX, was used in a molecular docking study to shed light on the molecular mode of 
action. The OXAZ-1 molecule was docked on the MDM2 and MDMX hydrophobic clefts 
using the Molecular Operating Environment (MOE) software (MOE, version 2013.08) 
(Chemical et al., 2013) and the crystallographic structures with PDB code 3LBL (MDM2) 
and 3LBJ (MDMX) allowing ranking the docking poses by binding affinities. On the following 
discussion, only the top ranked conformation was used. 
Recently (Soares et al., 2014b) we have re-docked the MI-63 analog co-crystallized MDM2 
ligand present in the 3LBL structure and a similar predicted pose was obtained, with a root 
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mean square deviation between the heavy atoms of the predicted and co-crystallized poses 
of 1.65 Å. The WK298 molecule was also re-docked on the MDMX using the 3LBJ structure. 
It was found that the protocol could also reproduce the crystallographic pose re-creating, 
this way, the main interactions between the molecule and the protein structure. This defined 
a rigid protein docking protocol that was also used to predict the pose for OXAZ-1 in MDM2 
and MDMX and is described in the experimental section. 
MDM2 and MDMX share high sequence homology in their p53 binding domains and interact 
with three key hydrophobic residues of p53: Phe19, Trp23 and Leu26. Between MDM2 and 
MDMX, p53 interacts in a similar but not identical hydrophobic cleft with the same three 
Phe19, Trp23 and Leu26 pockets although for instance, around the latter, some residues 
are different between both structures (Zhao et al., 2013a). 
The docking of OXAZ-1 in MDM2 and MDMX led to a similar prediction for the binding 
energy: -6.76 kcal/mol in MDM2 and -6.80 kcal/mol in MDMX. However, a visual inspection 
of the binding interactions established between OXAZ-1 with MDM2 and MDMX shows two 
different binding modes. 
Figure 19 shows the two proteins superposed with the OXAZ-1 top ranked docking poses 
obtained for each protein. In both poses, the aromatic part of the tosyl moiety is located in 
the Trp23 pocket, mimicking this hydrophobic interaction. However, the remaining of the 
molecule interacts with the two proteins in different zones.  
 
 
 
 
 
 
 
 
 
 
Figure 19. Docking pose of OXAZ-1 within the MDM2 and MDMX hydrophobic clefts limits depicted 
with a surface (in green, hydrophobic; in pink, hydrophilic areas). LEU54 and ILE61 are highlighted and 
CH-π interactions are displayed through doted lines. The OXAZ-1 pose found with the MDM2 structure is 
represented with carbon atoms in orange and the one for MDMX is represented with carbon atoms in blue. 
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In MDM2, the indole moiety of OXAZ-1 makes CH-π interactions with Leu54 and this moiety 
occupies the area reserved for hydrophobic interactions by Leu26 of p53. In MDMX, the 
MDM2 Phe55 is substituted by an histidine with a different side chain conformation that 
decreases the size of the cleft near Leu54 and prevents a similar pose as in MDM2. 
However, this histidine is able to make a CH-π interaction with OXAZ-1 allowing the carbon 
chain of OXAZ-1, containing the piperidone moiety, to sit on a cleft that runs alongside this 
residue. The indole moiety in this pose is located in the region defined by the p53 Phe19 
residue. 
 
2.3 Discussion 
In this work, a yeast target-directed assay was used for the screening of inhibitors of the 
p53-MDM2/X interaction. From the analysis of a small library of tryptophanol-derived 
oxazolopiperidone lactams, the N-tosylindole OXAZ-1 was identified as a potential dual 
inhibitor of the p53 interaction with MDM2 and MDMX. The assessment of the predicted 
binding model of OXAZ-1 to MDM2 and MDMX, by computational docking, and the co-IP 
assay in tumor cells supported the results from yeast, showing that OXAZ-1 is a putative 
inhibitor of MDM2 and MDMX, blocking their interactions with p53. 
The analysis of the in vitro antitumour activity revealed that the tumour growth inhibitory 
effect of OXAZ-1 was highly dependent on p53. Moreover, in conformity with the results 
from yeast, OXAZ-1 exhibited typical hallmarks of a dual inhibitor of MDM2 and MDMX (Li 
and Lozano, 2013). Particularly, it decreased the proliferation of wt p53-carrying tumour 
cells, an effect associated with the induction of cell cycle arrest and apoptosis. Additionally, 
it led to the stabilization of the p53 protein levels, that indicates an inhibition of the MDM2-
mediated p53 degradation by OXAZ-1, and up-regulation of the p53 transcriptional activity 
increasing the protein levels of the p53 target genes MDM2, MDMX, p21, Bax and Puma. 
Finally, it presented reduced antitumour activity against tumours without p53. Beyond that, 
like RO-5963, OXAZ-1 efficiently reduced the proliferation of wt p53-carrying tumour cells 
with high levels of MDMX (MCF-7 cells). In fact, also in MDMX-overexpression tumour cells, 
OXAZ-1 induced cell cycle arrest and apoptosis, led to p53 stabilization, and up-regulated 
p53 transcription targets involved in cell cycle and apoptosis. OXAZ-1 therefore overcame 
the commonly reported (Graves et al., 2012; Patton et al., 2006; Wade et al., 2006) 
resistance of MDMX-overexpression tumour to MDM2-only inhibitors. 
Cancer cell mitochondria are structurally and functionally different from their normal 
counterparts. Additionally, tumour cells are more susceptible to mitochondrial perturbations 
than the normal cells. Based on this, mitochondrially-targeted agents have emerged as a 
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promising approach to selectively eradicate chemotherapy-refractory cancer cells (Fulda et 
al., 2010). In fact, the (re)activation of cell death programmes by pharmacological agents 
that induce or facilitate mitochondrial membrane permeabilization (MMP) have emerged as 
an attractive strategy for cancer treatment (Fulda et al., 2010). MMP can be triggered by 
agents that increase cytosolic calcium or stimulate ROS generation. Moreover, MMP can 
be favoured by pro-apoptotic proteins of the Bcl-2 family, such as Bax. In fact, during 
apoptosis, Bax is translocated from the cytosol to mitochondria where it triggers MMP 
(Chipuk et al., 2004; Fulda et al., 2010). MMP results in the immediate ∆ψm dissipation, with 
the consequent release of pro-apoptotic factors into the cytosol, such as cyt c (Fulda et al., 
2010). The results obtained in the present work showed that OXAZ-1 also targets 
mitochondria of tumour cells. Actually, OXAZ-1 potently triggered a mitochondrion-centered 
apoptotic cell death characterized by ROS generation, Bax translocation to mitochondria, 
∆ψm dissipation, and the subsequent mitochondrial cyt c release.  
The pharmacological activation of the p53 pathway can be exploited to work in combination 
with other therapeutic agents to promote cell death via p53-dependent and -independent 
mechanisms. It is still not completely understood how drug combinations with p53 activators 
can lead to synergistic enhancement of cell death and improved therapeutic efficacy in the 
cancer treatment (Hoe et al., 2014). In spite of this, examples were already reported 
showing the efficacy of such combinations in anticancer treatment. This is the case of nutlin-
3a, which has shown excellent results when combined with non-targeted genotoxic agents, 
such as mitotic inhibitors, CDK inhibitors, DNA-damaging agents, and radiation therapy 
(Hoe et al., 2014; Wade et al., 2013). Based on this, the potential antitumour activity of 
OXAZ-1 is therefore strengthened in this work by showing that this compound may prime 
tumour cells for death induced by chemotherapeutic drugs, such as etoposide and 
doxorubicin. The prospect of combining conventional chemotherapeutic agents with OXAZ-
1 represents a promising strategy to minimize the emergence of resistance and to achieve 
maximal therapeutic responses with minimal side effects in cancer therapy. 
In summary, several evidence are provided in this work for the significant potential of OXAZ-
1 as an anticancer agent. The in vitro antitumour activity of OXAZ-1 is attributable to the 
selective activation of the p53 pathway involving the potential dual inhibition of MDM2 and 
MDMX. Additionally, OXAZ-1 leads to the (re)activation of a mitochondria-mediated cell 
death programme, being highly effective in combination with conventional therapies by 
increasing the antitumour outcome at very low concentrations.  
Although further work is still required to completely clarify the interaction of N-tosylindole 
OXAZ-1 with MDM2 and MDMX, relevant insights about its mode of action are provided in 
this study (Figure 20). Besides, this study opens the way to a new class of selective 
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activators of the p53 pathway, based on a tryptophanol-derived oxazolopiperidone lactam 
scaffold, with promising antitumour properties either isolated or in combined therapies. 
Additionally, the identification of N-tosylindole OXAZ-1 may be the first step toward the 
development of promising dual inhibitors of the p53-MDM2/MDMX interaction.  
 
 
 
Figure 20. Proposed molecular mechanism underlying OXAZ-1 antitumour activity. As putative dual 
inhibitor of the p53 interaction with MDM2 and MDMX, OXAZ-1 leads to p53 stabilization and to the 
subsequent activation of p53 transcriptional activity with increased levels of p53 target proteins, as MDMX, 
MDM2, p21, Bax and PUMA. The increase of p21 levels leads to a G0/G1 cell cycle arrest. The increase 
of PUMA and Bax leads to the activation of a mitochondrial apoptotic pathway, involving Bax translocation 
to mitochondria, ROS production, ∆Ѱm dissipation, and cyt c release. The release of cyt c from 
mitochondria triggers the activation of a caspase pathway with PARP cleavage; *p53 target genes. 
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Chapter 3 
. Development of a yeast target-
directed screening assay for 
biological and pharmacological 
studies of mutant p53 
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3 Introduction 
About half of all human tumours express inactive mut p53 forms, which often correlates with 
high resistance to conventional chemotherapy and poor prognosis [reviewed in (Freed-
Pastor and Prives, 2012; Girardini et al., 2014)]. Besides their high prevalence, expression 
of mut p53 is restricted to tumour cells, which makes the pharmacological restoration of wt 
activity to mut p53 an appealing and selective therapeutic strategy for anti-cancer therapy 
[reviewed in (Farnebo et al., 2010)]. 
In the present work, it was developed a new yeast target-directed screening assay for the 
identification of reactivators of some of the most prevalent mut p53 forms, namely R175H, 
R273H, R280K and Y220C. In order to validate this yeast assay, known small molecules 
reactivators of the expressed mut p53 were used. The developed yeast target-directed 
screening assay is easily adapted for the high-throughput screening of large libraries of 
small molecules. Additionally, the obtained transformed cells can be used in the study of 
the biology of the expressed mut p53 forms. 
 
3.1 Material and methods 
3.1.1 Plasmids and compounds. 
The yeast expression vectors pLS89-(TRP1), encoding human wt p53 under the control of 
GAL1-10 inducible promoter (kindly provided by Dr. Richard Iggo; Swiss Institute for 
Experimental Cancer Research, Switzerland), and pTS76-(LEU2), encoding human mut 
p53 R280K, R273H, R175H or Y220C under the control of ADH1 constitutive promoter 
(kindly provided by Dr. Gilberto Fronza; IST Istituto Nazionale per la Ricerca sul Cancro, 
Genoa, Italy), were used. 
PRIMA-1 and CP-31398 were purchased from Sigma-Aldrich (Sintra, Portugal), and 
Phikan083 from Tocris (Biogen Cientifica, Madrid, Spain). All tested compounds were 
dissolved in DMSO from Sigma–Aldrich (Sintra, Portugal). 
 
3.1.2  Yeast strain, transformation, and growth conditions 
For the yeast assay, S. cerevisiae (strain CG379, α ade5 his7-2 leu2-112 trp1-289α ura3-
52 [Kil-O]; Yeast Genetic Stock Center) was transformed with a plasmid encoding human 
wt p53 or the respective empty vector (pLS89; yeast control). To express a panel of human 
mut p53, yeast cells were transformed with a plasmid encoding the human mut p53 R280K, 
R273H, R175H or Y220C, or with the respective empty vector (pTS76). The plasmids used 
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in the yeast transformation process were first amplified in Escherichia coli DH5α from 
Lucigen (Frilabo, Porto, Portugal) and subsequently extracted using the GenEluteTM HP 
Plasmid Miniprep Kit from Sigma-Aldrich (Sintra, Portugal). After extraction, yeast strains 
were transformed using the LiAc/SS Carrier DNA/PEG method as described in (Gietz and 
Schiestl, 2007). For selection of transformed S. cerevisiae, cells were routinely grown in a 
minimal selective medium with 2% (w/w) glucose, 0.7% (w/w) yeast nitrogen base without 
amino acids from Difco (Quilaban, Sintra, Portugal) and all the amino acids required for 
yeast growth (50 µg/mL) except leucine (for pTS76 vector) or tryptophan (for pLS89 vector), 
to approximately 1 OD600. 
To induce expression of human proteins, yeast cells were diluted to 0.05 OD600 in induction 
selective medium containing 2% (w/w) galactose and 1% (w/w) raffinose (instead of 
glucose). Yeast cells were incubated at 30 ºC under continuous orbital shaking (200 r.p.m.) 
for approximately 30 h (time required by the control yeast, transformed with the empty vector 
pLS89 or pTS76, to achieve 0.4 OD600). Yeast growth was analysed by counting the number 
of CFU after 2 days incubation at 30 ºC on Sabouraud Dextrose Agar (Liofilchem). 
 
3.1.3 Yeast protein extraction and Western Blot analysis 
To analyse protein expression levels in yeast, samples were lysed with CellyticTM Y Cell 
Lysis Reagent containing EDTA-free protease inhibitor cocktail from Sigma-Aldrich (Sintra, 
Portugal). Following protein extraction, whole protein extracts were quantified using the 
Coomassie staining Bradford from Sigma–Aldrich (Sintra, Portugal). Proteins (40 µg) were 
electrophoresed on 10% (Acrylamide) SDS-PAGE and transferred to a Whatman 
nitrocellulose membrane from Protan (VWR, Carnaxide, Portugal). Membranes were 
blocked with 5% milk and probed with a mouse monoclonal anti-p53 (DO-1), followed by an 
anti-mouse horseradish-peroxidase (HRP)-conjugated secondary antibody both from Santa 
Cruz Biotechnology (Frilabo, Porto, Portugal). For loading control, membranes were 
stripped and reprobed with a mouse monoclonal anti-yeast phosphoglycerate kinase 
(Pgk1p) antibody from Alfagene (Molecular probes, Carcavelos, Portugal), followed by an 
anti-mouse horseradish-peroxidase (HRP)-conjugated secondary antibody. The signal was 
detected with the ECL Amersham kit from GE Healthcare (VWR, Carnaxide, Portugal) and 
the Kodak GBX developer and fixer are from Sigma-Aldrich (Sintra, Portugal). Band 
intensities were quantified using the Bio-Profil Bio-1D++ software (Vilber-Lourmat, Marne 
La Vallée, France). 
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3.1.4 Yeast growth screening assay 
Yeast cells were incubated in induction selective medium in the presence of 0.1 – 200 μM 
of positive controls (PRIMA-1 and CP-31398 for R280K, R273H and R175H and Phikan083 
for Y220C) or 0.1% DMSO only, for approximately 30 h, at 30 oC, under continuous orbital 
shaking. Yeast cell growth was analysed as described in section 3.1.2. Results were 
estimated considering as 1 the growth inhibitory effect caused by the expression of wt p53 
in yeast cells incubated with DMSO only. 
 
3.1.5 Statistical analysis 
Data were analysed statistically using the GraphPad software. Differences between means 
were tested for significance using the Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001). 
 
3.2 Results 
In this work, the individual expression of human mut p53 R280K, R175H, R273H and Y220C 
in yeast was confirmed by Western blot analysis (Figure 21A). This analysis showed no 
significant differences among the protein expression levels of wt and mut p53 forms in yeast. 
Additionally, the analysis of the growth of yeast cells expressing mut p53 showed that, 
contrary to wt p53 (Coutinho et al., 2009), none of the human p53 mutants interfered with 
the yeast cell growth, when compared to the empty vector (Figure 21B). 
A B 
Figure 21. Effect of wt and mut p53 forms in yeast cell growth. (A) Expression of human wt or mut 
p53 R280K, R175H, R273H or Y220C in yeast was confirmed by Western blot analysis; Pgk1p was used 
as loading control. (B) Effect of mut p53 forms on yeast cell growth; yeast cells were incubated in induction 
selective medium for 30 h; the growth of yeast expressing mut p53 R280K, R273H, R175H or Y220C was 
analysed by CFU counts; growth was evaluated considering the growth of control yeast (empty vector) 
as 100%; data are mean ± S.E.M. of three to five independent experiments. Immunoblots represent one 
of two independent experiments; Pgk1p was used as loading control; 
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The efficacy of this yeast assay for the screening of reactivators of mut p53 forms was 
thereafter assessed by testing known reactivators of the respective mutants, namely 
PRIMA-1 (Bykov et al., 2002) and CP-31398 (Foster et al., 1999) for human mut p53 R280K, 
R273H and R175H and Phikan083 for human mut p53 Y220C (Boeckler et al., 2008) (Figure 
22). Briefly, this yeast assay is based on the fact that, as in mammalian cells [reviewed in 
(Freed-Pastor and Prives, 2012)], mut p53 forms are inactive in yeast, and therefore do not 
induce yeast growth inhibition (Figure 22B). Based on this, reactivators of mut p53 should 
re-establish the wt p53 activity (inhibitory growth effect) to mut p53 expressed in yeast 
(Figure 22A). 
 
 
 
 
 
Figure 22. Development of a new yeast target-directed screening assay for the identification of 
reactivators of mut p53 forms. (A) Schematic representation of the yeast target-directed screening 
assay. Similar to human cells, in yeast, the transcriptional activity of wt p53 is conserved inducing growth 
inhibition, while the non-functional mut p53 does not affect the yeast growth. In these assay, reactivators 
of mut p53 re-establish the wt p53 activity (growth inhibitory effect). (B) Effect of positive controls on the 
growth of yeast cells expressing mut p53; yeast cells were incubated in induction selective medium in the 
presence of 50 μM of PRIMA-1 or CP-31398 (positive controls for R280K, R175H and R273H), or 50 µM 
of PhiKan083 (positive control for Y220C), or DMSO only, for 30 h; the effect of positive controls on the 
growth of yeast expressing mut p53 (R280K, R273H, R175H or Y220C) was analysed by CFU counts; the 
growth inhibitory effect caused by wt p53 expressed in yeast cells incubated with DMSO only was set as 
1; data are mean ± S.E.M. of three to five independent experiments; values significantly different from 
DMSO only are indicated (*p < 0.05, **p < 0.01; ***p < 0.001 unpaired Student’s t-test). 
A B 
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In this assay, yeast cells expressing R280K, R175H, R273H or Y220C were incubated with 
0.1 µM - 200 µM of CP-31398, PRIMA-1 or PhiKan083. The CP-31398 only re-established 
the wt p53 activity to R280K and R273H at 50 µM, having no significant effects on p53 
R175H (Figure 22B). Additionally, our yeast assay was able to detect the reestablishment 
of the wt p53 function to mut p53 R280K, R175H or R273H by 50 µM of PRIMA-1 (Figure 
22B). Finally, the compound PhiKan083 re-established the wt p53-induced growth inhibition 
to mut Y220C at 50 µM (Figure 22B). It was shown that concentrations of CP-31398, 
PRIMA-1 and PhiKan083 higher than 50 µM did not increase the p53 activity. Furthermore, 
at 100 µM and 200 µM, CP-31398 and PRIMA-1, respectively, exhibited cytotoxic effects 
on control yeast (empty vector). For Phikan083 no cytotoxic effects were observed for all 
the concentrations tested (data not shown). 
 
3.3 Discussion 
The possibility of a more direct and simplified analysis of the human p53 pathway may 
eliminate the effects of redundant processes on the measured output [reviewed in (Pereira 
et al., 2012a)]. In fact, the yeast model has already proven its value in the study of human 
mut p53. Actually, several groups have devoted much time in the study of the transactivation 
function of TP53 mutants in yeast, establishing that, when compared to wt p53, nearly all 
mutants at p53 “hotspot” residues lost or retain only a very weak transactivation function 
[reviewed in (Bisio et al., 2014)]. For example, yeast p53 transactivation assays have been 
extensively used to study the impact of mutations on wt p53 transcriptional activity 
(Andreotti et al., 2011; Monti et al., 2007; Monti et al., 2011). Additionally, the impact of 
using “humanized yeast systems” in the identification of pharmacological regulators of 
human p53 has already been proven by our group (Leão et al., 2013a; Leao et al., 2013; 
Leão et al., 2013b). 
The selection of the mut p53 forms to be expressed in yeast relied on its prevalence in 
human tumours, and on its association to resistance to conventional chemotherapeutic 
agents. In addition, it was also our intention to express both structural (R175H and Y220C) 
and contact (R273H and R280K) mut p53s (Boeckler et al., 2008; Cho et al., 1994). Among 
the mut p53 tested, the mut R175H, R273H and Y220C, are some of the most frequent 
mutations in human cancers [reviewed in (Girardini et al., 2014)]. Moreover, the mut p53 
R280K is associate to triple-negative breast cancers (as breast adenocarcinoma MDA-MB-
231 tumour cells), which do not respond to the conventional chemotherapy (Foulkes et al., 
2010). 
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This work confirmed the results obtained in in vitro and in in vivo studies with CP-31398, in 
which it was shown that this compound was able to re-established the wt p53 activity to mut 
p53 R280K, R175H and R273H (Foster et al., 1999). In spite of this, contrary to that reported 
in mammalian cells (Foster et al., 1999; Mehta et al., 2007), in the yeast cell system, Tanner 
and colleagues were unable to detect reactivation of mut p53 R175H and R273H (Tanner 
and Barberis, 2004) by CP-31398. Accordingly, in our yeast assay, CP-31398 was also 
unable to reactivate the wt p53 activity in mut p53 R175H. Further studies must be done in 
order to confirm this absence of effect of CP-31398 on mut p53 R175H in yeast.  
Concerning to PRIMA-1, in vitro studies in human tumour cells showed that this compound 
restores the sequence specific DNA-binding and transcriptional transactivation to mut p53 
R280K, R273H and R175H (Bykov et al., 2002; Bykov et al., 2005; Mehta et al., 2007). 
Besides, in vivo studies reported that PRIMA-1 suppressed the tumour-cell growth in mice 
by inducing apoptosis (Lambert et al., 2009). Although previous efforts of other authors to 
demonstrate the activity of this compound as reactivator of mut p53 in yeast were 
unsuccessful (Andreotti et al., 2011), in this work, it was shown that PRIMA-1 was also able 
to re-establish the wt p53 function to mut p53 R280K, R175H and R273H in yeast. 
Concerning to PhiKan083, identified through a rational design approach, this small molecule 
selectively binds to a cavity on p53 surface created by the Y220C mutation, restoring the 
wt p53 activity to mut p53 Y220C in human tumour cells (Liu et al., 2013). Our yeast assay 
was also able to reproduce these results.  
Altogether, in the present work, with the reconstitution of human mut p53 R280K, R175H, 
R273H and Y220C regulatory pathways in yeast, a simplified yeast target-directed growth 
inhibitory assay was developed to search for reactivators of some of the most prevalent mut 
p53 forms. This yeast phenotypic assay is based on simple measurements of the yeast cell 
growth and therefore can be adapted to the high-throughput screening of large chemical 
libraries in a cost-effective manner. This cell model can also help in the elucidation of the 
biology of mut p53 forms. 
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4 General conclusions and final remarks 
Cancer is one of the greatest medical concerns of the current aging population. The efficacy 
of the therapeutic options currently available remain limited and, in most cases, the 
treatment is accompanied by severe side effects. Accelerating the discovery process of 
more efficient and selective anticancer agents is therefore of enormous interest, both from 
economic and medical standpoints [reviewed in (Kumar et al., 2009)]. 
The p53 protein is a major transcription factor with a crucial role in the regulation of major 
cellular processes including DNA repair, cell proliferation and death. Its relevance as a 
tumour suppressor is highlighted by the fact that the p53 activity is lost in all human tumours 
either by mutation of the TP53 gene or by inactivation through interaction with negative 
regulators, particularly MDM2 and MDMX. Based on this, p53 has been considered a key 
therapeutic target in cancer treatment. In fact, since the discovery of p53 as the “guardian 
of the genome”, amazing efforts have been developed in order to find molecular strategies 
to re-establish the p53 function. In this context, inhibitors of the p53 interaction with MDM2 
and MDMX and reactivators of mut p53 activity have been considered promising therapeutic 
approaches in cancers with wt and mut p53 forms, respectively. In spite of this, to date, only 
two inhibitors of the p53 interaction with MDM2 and MDMX were described. These type of 
small-molecules are very required for a full activation of the p53 function in tumours with wt 
p53. Additionally, although several small-molecules have been identified that reactivate the 
wt p53 function to a wide range of mut p53 forms, only few compounds have been described 
as true reactivators of mut p53 (Collavin et al., 2010). Additionally, low selectivity to the p53 
pathway, unfavorable pharmacokinetic and toxicity profiles make the search for new 
pharmacological alternatives highly required. 
In the present work, using a previously developed yeast-based screening approach, a 
potential dual inhibitor of the p53 interaction with MDM2 and MDMX was identified, the N-
tosylindole OXAZ-1. OXAZ-1 exhibits a p53-dependent in vitro antitumour activity against 
tumour cells retaining wt p53 and distinct levels of MDM2 and MDMX. The antitumour 
activity of OXAZ-1 is reinforced by its ability to trigger a mitochondria-mediated apoptotic 
cell death, and by its synergic effects with conventional chemotherapeutic drugs. Although 
much work remains to be done to completely clarify the molecular mechanism of OXAZ-1, 
several relevant insights about the mode of action of this compound are already provided 
in this study. Additionally, this work opens the way to a new class of activators of the p53 
pathway (dual inhibitors of MDM2 and MDMX), based on a tryptophanol-derived 
oxazolopiperidone lactam scaffold, with promising antitumour properties either isolated or 
in combined therapies. 
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Moreover, in this work, new yeast target-directed screening assays were developed to 
search for reactivators of some of the most prevalent human mut p53 forms, namely R280K, 
R175H, R273H and Y220C. In fact, using this approach, a new reactivator of mut p53 
R280K, the oxazoloisoindolinone SLMP53-1, under international patent request (Soares et 
al., 2014a), was recently discovered by our group. The antitumour activity and molecular 
mechanism of action of SLMP53-1 was thereafter validated in in vitro and in vivo animal 
models. A proof-of-concept was therefore provided for the efficacy of these assays to 
search for reactivators of mut p53. The enlargement of these assays to other mut p53s will 
certainly accelerate the discovery of reactivators of these proteins. Finally, it must be 
highlighted that these yeast assays may be also used to study the biology of these mut p53-
R280K, R175H, R273H and Y220C. Actually, these assays may represent a relevant tool 
for the further elucidation of the mut p53 network, which remains largely unknown. 
As a whole, with this project a relevant contribution was provided to the pharmacology of 
p53 with the identification of a promising small-molecule that can be further explored as 
potential anticancer agent. Additionally, it improved our anticancer drug discovery strategy 
with the implementation of new screening assays for relevant target proteins in cancer. 
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